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ABSTRACT      
Macrophage-infiltration of adipocytes in obesity provides an important mechanistic link 
that may explain the increase in inflammatory mediators produced by adipose tissue. 
Elucidating the crosstalk mechanisms between macrophages and adipocytes is important 
as adipose tissue has been shown to be the linchpin linking inflammation and insulin 
resistance. Growing evidence suggests that vitamin D exerts immunomodulatory effects 
and adipose tissue could be a target for its action. This study investigated the role of 
vitamin D3 (calcitriol) in alleviating inflammation mediators expressed and released by 
human adipocytes under the basal and stimulated conditions. The study also examined 
the effect of calcitriol on monocyte migration as well as on the NF-κB and MAPK 
signalling pathways.  
 
A simulated model of adipocyte inflammation was created by incubating adipocytes with 
macrophage-conditioned (MC) medium, and this model was then used to study the effect 
of vitamin D. High dose calcitriol (10-8M) decreased the basal levels of MCP-1 and IL-6 
released by adipocytes. Pretreatment with calcitriol (10-8M) reduced the rise in protein 
levels of MCP-1 and IL-6 released by adipocytes after stimulation with MC medium. 
Calcitriol (10-8M) also decreased IL-6 release but it had no effect on MCP-1 production 
by adipocytes stimulated with TNF-α. Upon MC medium stimulation, calcitriol (10-8M) 
partially reversed the decrease in gene expression of adiponectin and ZAG although the 
release of adiponectin or ZAG by adipocytes was unaffected. In addition, calcitriol (10-
11M and 10-8M) supplementation decreased THP-1 macrophage migration although it did 
not reverse the effects of MC medium or TNF-α. Furthermore, calcitriol increased the 
basal protein abundance of NF-κB IκBα and reversed the inhibitory effect of MC medium 
on IκBα. Calcitriol supplementation also decreased both basal and MC medium 
stimulated protein abundance of phosphorylated NF-κB p65 as well as basal and MC 
medium stimulated levels of phosphorylated p38 MAPK. 
 
In conclusion, this study has shown that MC medium potently stimulated inflammatory 
responses in human adipocytes. Calcitriol supplementation was able to reduce the basal 
and stimulated production of the proinflammatory mediators by adipocytes. Calcitriol 
also led to a decrease in chemoattractant ability of adipocytes. In addition, calcitriol 
exhibited an inhibitory effect on the activation of the NF-κB and MAPK signalling 
pathways. These results suggest that calcitriol may have a beneficial effect in protecting 
against adipose tissue inflammation induced by the crosstalk between macrophages and 
adipocytes. 
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1.1 The Adipose Organ 
1.1.1 Adipose tissue anatomy 
As defined by Cinti (2009), an organ is defined as an anatomically dissectible structure 
with a discrete gross anatomy comprising at least two different tissues. The adipose organ 
is made up of adipocytes suspended as white adipose tissue (WAT) and brown adipose 
tissue (BAT) in intermingled in a stromal vascular fraction (SVF) in a connective tissue 
matrix of collagen, vascular and nerve tissue. Although the gross anatomy of the human 
adipose organ has never been described in detail, it is understood to be composed of 
several subcutaneous, visceral and intermuscular depots. Much of our understanding is 
based on the morphological similarities between humans and rodents. The subcutaneous 
depot is in continuity with dermal adipose tissue, not confined to specific areas and 
presents as a continuous layer beneath the skin. Mammary and gluteo-femoral 
subcutaneous adipose tissue tends to be more developed in females compared to males 
(Cinti, 2006). Visceral depots in humans correspond to those in rodents, mainly locating 
at the thorax and abdomen cavities. Recent observations suggest that the omental depot is 
particularly well developed in humans compared to the relatively small omental depot in 
mice. Periepididymal adipose tissue, found in rodents, is not present in humans. Human 
adipose tissue exhibits greater complexity; variable amounts of adipocytes can be found 
in the parotid, parathyroid, bone marrow, pancreas, thymus, lymph nodes and other minor 
locations. The weight of the human adipose organ of lean adults is about 8–18% of the 
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body weight in males and 14–28% in females (Cinti, 2009). Adipose tissue turnover in 
humans is dynamic and approximated at 10% annually for all humans. 
Classically, adipose tissue functions primarily as a fat depot for the body and stores 
energy in the form of triglycerides. As such, approximately 90% of the adipocyte is made 
up of triglycerides, with the remaining 10% consisting of cytoplasm, mitochondria, 
nucleus and other organelles (Björntorp and Ostman, 1971). 
1.1.1.1 White adipose tissue 
WAT is mainly found in the subcutaneous and visceral depots in humans, mice and rats 
and is known to function as a long-term fuel repository for the organism as a whole, with 
a considerable caloric value compared to carbohydrates (39.1 KJ/g to 15.4-17.5KJ/g). It 
is the main form of energy storage, comprising 20 to 25% of the body weight in humans 
because of its low water content (Trayhurn, 2007). From the evolutionary standpoint, 
water content associated with the storage of carbohydrates as an energy source is 
disadvantageous as it would render terrestrial mammals immobile - hence the preferential 
storage of lipids. The white adipocyte is typically white in appearance and are typically 
unilocular, with a single large lipid droplet comprising >90% of the cell’s volume (Figure 
1.1). It is present in WAT is found throughout the body, with the largest depots found in 
subcutaneously and surrounding the viscera. White adipocytes have a fairly variable size 
throughout the body which depends largely on the amount of lipid storage. Electron 
microscopic examination shows no distinct structure separating it from the thin rim of 
cytoplasm, although perilipin is generally known to exist at the periphery (Blanchette-
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Mackie, 1995; Greenberg, 1991). WAT mitochondria are thin and elongated, with 
randomly oriented cristae. A distinct basal membrane surrounds the adipocyte and several 
caveolae can be found on the outer surface. 
1.1.1.2 Brown adipose tissue 
Brown adipose tissue is found integrated within WAT depots and functions as a heat 
producer through non-shivering thermogenesis. Physically it contrasts well with WAT, 
characterised by the brown adipocyte’s brown colour and multilocular appearance. It is 
characterised by high tissue vascularisation in BAT contributing to its brown appearance. 
Brown adipocytes are mostly polygonal and possess variable diameters ranging from 15 
to 50 µm (Cinti, 2009).  The subcutaneous interscapular brown adipose tissue depot has 
been well-studied in rodents. Activation is facilitated by postganglionic sympathetic 
nerves that unilaterally innervate the two interscapular brown adipose tissue lobes and 
forms a dense network of unmyelinated fibres which reaches virtually every cells by 
noradrenaline release though varicosities (De Matteis et al. 1998). This innervations is 
essential for the thermogenic ability of brown adipose tissue. Parasympathetic 
innervations in BAT is generally absent with the exception of pericardial and mediastinal 
BAT (Giordano et al. 2004; Schafer et al., 1998). 
In addition, BAT possess type II thyroxine-5’deiodinase that generates a high 
triiodothyronine concentration within the tissue. BAT also harbours abundant 
mitochondria, distinguished ultrastructurally by the discovery of densely packed cristae 
(Néchad, 1986). The difference in cristae morphology within BAT mitochondria is 
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indicative of its high energy dissipation role as these characteristics are usually associated 
with energy demanding processes e.g. cardiac myocytes. Perhaps the most unique feature 
of BAT is its expression of Uncoupling protein-1 (UCP1), a 32-kDa protein embedded 
within the inner mitochondrial membrane. UCP-1 functions to uncouple mitochondrial 
respiration, giving BAT its ability to generate energy from the stored fatty acids 
independent of ADP availability. UCP1 can be found exclusively in brown adipocytes 
although there have been accounts of low-level UCP-1 expression in thymocytes (Carroll 
et al., 2004). Upon exposure to cold temperatures, thermoceptors elicit subcutaneous 
thermal afferent signals which are then transmitted to the brain, resulting in non-shivering 
thermogenesis in BAT (Morrison, 2004). Neuronal studies on the thermal somatosensory 
reflex suggest that peripheral thermoceptors transmit cold sensation through afferent 
neuronal projections to the preoptic area (POA) in the rostral hypothalamus (Morrison et 
al. 2008). When thermoneutrality is reached, efferent inhibitory neurons originating from 
the POA to the dorsal medial hypothalamus and the brain stem tonically block 
sympathetic outflow to BAT (Nakamura and Morrison, 2008). Brown fat has been shown 
to counteract obesity and metabolic disease in studies (Lowell et al., 1993). Specifically, 
rodent studies have shown that mice with higher amounts of brown fat gain less weight, 
have greater insulin-sensitivity and lower levels of serum free fatty acids (Kopecky et al., 
1995, 1996; Cederberg et al., 2001). 
1.1.1.3 Brite cells 
In recent years, “brite” or “beige” cells have been identified, which are postulated to be 
the intermediates of white and brown adipocytes (Ishibashi and Seale, 2010). These cells 
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are derived from a different cell lineage than native BAT, but possess the ability to 
generate heat by mitochondrial uncoupling similar to BAT cells. Prolonged exposure to 
cold or β3-adrenergic agonists in white adipose tissue can cause tissue 
transdifferentiation to beige adipose tissue (Seale et al., 2009). Rodent studies have 
shown that white adipocytes in mice increase expression of the enzyme cyclooxygenase-
2 (COX-2) in response to cold temperatures or β3-adrenergic agonists, which 
consequently produces prostaglandins (Vegiopoulos et al., 2010). Prostaglandins 
produced by white fat cells or from the circulation stimulate the formation of 
thermogenic beige cells in white fat. It is not clear if beige cells arise from unique 
precursor cells or by transdifferentiation of white fat cells (Vegiopoulos et al., 2010). 
Overexpression of COX-2 induced ectopic beige fat development and showed a 20% 
reduction in body weight correlating with a severe reduction in body fat content. Oxygen 
consumption and body temperature has been shown to increase in transgenic mice 
overexpressing COX-2, reflecting a significant elevation of the resting metabolic rate. 
Plasma free fatty acid and glycerol levels were also lower in the transgenic mice 
(Vegiopoulos et al., 2010). The current evidence suggests that beige fat development via 
the COX-2-prostaglandin pathway contributes positively to adaptive thermogenesis and 
energy homeostasis. 
1.1.1.4 Stromal vascular fraction 
Non-adipocyte cells make up the SVF in adipose tissue. It consists of its constituent cells, 
sympathetic nerves, connective tissue and extracellular matrix. Collagen, elastic fibres 
and resident fibroblasts maintain the integrity of the ECM, creating a define tissue mass 
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and the boundaries of individual adipose tissue depots. The stromal vascular fraction 
(SVF) is a dynamic site of activity because of its known cellular constituents, namely the 
mesenchymal stem cells (MSC), T regulatory cells, endothelial precursor cells, 
macrophages and preadipocytes (Riordan et al., 2009). The SVF within various adipose 
tissue depots are known to harbour different proteomic profiles, establishing the 
distinction of characteristics between visceral adipose tissue and subcutaneous tissue and 
contributing to their differential metabolic properties. For example, Peinado et al. (2010) 
identified 24 genes differentially expressed in the SVF of VAT and ScAT. TBX15 
(Gesta, 2011) was found to be higher in visceral SVF compared to subcutaneous SVF, 
while Krüppel-like factor 4 and CAV-1 has recently been discovered to be downregulated 
in obesity and in lower quantities in visceral tissue SVF (Liao et al., 2011). Complement 
components C2, C3, C4, C7, and Factor B had higher expression in omental compared 
with subcutaneous adipose tissue. 
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Figure 1.1 White adipocyte and brown adipocyte 
 
   
WAT cells are characterised by a single large lipid vacuole and while the brown fat 
cell is characterised by numerous smaller lipid vacuoles and the presence of 
numerous mitochondria. Unilocular cells usually range from 25-200 microns in 
diameter, while multilocular cells are about 60 microns in diameter.  
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1.1.2 Adipose tissue function 
Adipose tissue is classically understood to function as energy storage depots in the form 
of fatty acids, so as to ensure adequate energy availability in between meals. It is also 
known to function as cushioning and insulation for the body. Most of its classical 
functions depend largely on WAT which is found in greater abundance within the 
adipose organ. Both BAT and WAT are similar with regard to its highly specialised 
biochemical functions, which include lipogenesis and lipolysis (Lowell and Flier, 1997). 
In the formation of triglycerides within an adipocyte, lipids are presented to the cell in the 
form of chylomicrons and VLDL cholesterol. Lipoprotein Lipase (LPL) present within 
the adipocyte breaks down the triglyceride contents of chylomicrons and VLDL 
cholesterol for incorporation into the adipocyte (Large et al., 2004). Hormone-sensitive 
lipase (HSL) triggers the breaking down the triglycerides within the adipocyte in 
response to hormonal signals such as corticotrophin, adrenaline, noradrenaline, TSH, 
Prolactin, LH and glucagon (Rodbell et al., 1970). Beyond its role in physical protection 
and energy regulation and conservationism, adipose tissue has been known for its role in 
steroid conversion as well as a secretory source of various bioactive substances. Its 
resultant designation as an endocrine organ comes with the discovery of heterogeneity of 
adipose tissue which come together to serve its multitude of functions. 
1.1.2.1 Heterogeneity of adipose tissue 
Although the cells of the adipose organ share common characteristics, the protean nature 
of the adipose organ is due to its variability at its levels of organization. At the cellular 
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level, white and brown adipocytes have opposite functions attributable to their 
intracellular makeup, giving them the respective roles of storing and dissipating energy.  
This attribute partly gives it the ability to act as a buffer for the flux of fatty acids in the 
circulation during the postprandial period, and emulates the role of the liver and skeletal 
muscles in buffering postprandial glucose fluxes (Frayn, 2002).The cells of adipose tissue 
are also known for its plasticity. Adipocytes demonstrate a formidable ability to enlarge 
reversibly and transdifferentiate macroscopically between BAT and WAT during 
development (Cinti, 2009). Its physical changes are often coupled with functional 
changes e.g. greater leptin secretion and higher free fatty acid output in hypertrophy. This 
seems to play a part in acclimatization and adaptation to environmental changes e.g. 
temperature fluctuations, pregnancy/lactation, obesity, fasting, and calorie restrictions 
(Cinti, 2009). SVF preadipocytes also show multiple differentiation potentials including 
osteogenic, chondrogenic, myogenic and neurogenic lineages (Prunet-Marcassus et al., 
2006). 
At the tissular level, the differences in locale and cellular morphology of adipose tissue 
cells determine the differences between adipose tissue function. Adipocyte size tends to 
be larger in subcutaneous depots compared to omental depots (Ostman et al. 1979; 
Rebuffe-Scrive et al., 1989; Reynisdottir et al., 1997). Lowered basal lipolysis, coupled 
with an increased sensitivity to insulinic anti-lipolytic activity is also more frequently 
associated with subcutaneous depots rather than visceral fat (Arner, 1995). These features 
seem to relate to their respective functions, whereby a greater surface area to volume 
ratio and a lesser metabolically active state in subcutaneous depots helps it to fulfil its 
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energy storage and lipid buffering capabilities. The richer vascularity and innervation of 
visceral adipose tissue and added portal drainage may be related to its function to provide 
direct hepatic access to FFAs and cortisolic functions in the liver. However, there is some 
evidence to suggest that adipocyte lipolysis may be more related to adipocyte size than 
regional origin (Edens et al., 1993; Farnier et al., 2003; Tchernof et al., 2006). 
Given the attributes highlighted so far in this chapter, it is quite plain to see that adipose 
tissue has a well-defined role in energy regulation, glucose homeostasis, lipid 
metabolism, sexual development and appetite control (Cousin et al. 1999). In recent years 
adipose tissue has been found to exhibit more characteristics playing important roles 
beyond its classical functions. In the spotlight is its potential impact on the immune 
system which has yet to be clearly elucidated. Adipose tissue is an important secretory 
source of adipokines, a diverse range of protein factors and signals (Trayhurn et al., 
2006). Adipokines are highly diverse in terms of protein structure and physiological 
function and it has been found that many are linked to the immune system. They include 
the classical proinflammatory cytokines (e.g. TNF-α, IL-6, IL-1β), chemokines 
(macrophage chemoattractant protein-1, IL-8, macrophage migration inhibitory factor) 
and inflammation-related moieties (e.g. leptin, ZAG and adiponectin; Trayhurn et al., 
2006). 
Just as its site-specific differences give rise to differential roles in lipid and glucose 
metabolism, this same heterogeneity has also been exhibited in inflammatory signalling. 
In particular, visceral adipose tissue mass correlates with the development of insulin 
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resistance. This has a lot to do with the greater metabolic activity in omental adipose 
tissue. The universally accepted opinion is that greater fatty acid contribution by 
metabolically active fat depots contributes to inflammation (Song et al., 2006, Nyugen et 
al., 2005, Tripathy et al. 2003). Adipose tissue has since been recognised as a major 
contributor to inflammatory status in physiology, as links between increased adiposity 
and inflammatory diseases continue to be identified. This provides a new impetus to 
study adipokine secretion in adipose tissue. 
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1.1.3 Adipose tissue alteration in obesity 
Obesity is defined as the increase in adiposity by the expansion of adipose tissue (Salans 
et al., 1971). It usually results from a long-term positive energy balance and occurs when 
energy intake exceeds energy expenditure. An increase in adiposity is broadly 
characterised by adipocyte hypertrophy and hyperplasia. The increases in adipocyte 
number and size have important implications in defining the composition of its 
secretome, its metabolic activity and ultimately adipose tissue behaviour. For example, 
adipocyte hypertrophy is associated with a rise in fatty acid release, as well as the 
adipokine leptin, cytokines IL-6, TNF-α as well as growth factor TGF-β. Other changes 
include the rarefaction of neural networks and vasculature in adipose tissue (Coppack, 
2005). Perhaps the most defining histological change in obesity is the infiltration of 
adipose depots by mononuclear cells (Wellen and Hotamisligil, 2003; Weisberg et al., 
2003). In particular, macrophage infiltration of adipose tissue has been shown to have 
important implications in the development of disease states associated with obesity. It has 
been recognised to be the linchpin between obesity, inflammation and insulin resistance. 
1.1.3.1 Macrophage infiltration in obesity 
SVF cells have been known to be major contributors of inflammatory mediators such as 
TNF-α and IL-6 in adipose tissue (Zeyda et al. 2007).  Not until recently were 
macrophages found to be the main contributors of inflammation in the SVF. 
Macrophages are found to associate in high numbers especially in omental tissue, 
contributing to a unifying hypothesis that explains the higher production of inflammatory 
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cytokines in visceral omental adipose tissue that leads to its observed predictability of 
comorbidities in obesity, including insulin resistance. 
Macrophage localization in the adaptive immune response is meant to be a beneficial and 
essential process in physiology. Its classical role is to prevent or destroy pathogens and 
the toxic molecules produced. A novel role for macrophages is the preservation of 
metabolic homeostasis. Macrophage infiltration is dynamically altered in response to 
lipid flux in lean or obese individuals, indicating the macrophage’s possible role in 
suppressing lipolytic signals (Kosteli et al., 2010). In obesity, the type and intensity of 
macrophage infiltration has important implications in the manifestation of obesity 
comorbidities. Not only is macrophage infiltration increased, so is the tendency for a 
phenotypic switch of macrophages from the M2 to the M1 state (Fujisaka et al, 2009). 
The M1 state is associated with the production of classical proinflammatory signals that 
generates Th1 responses and cell-mediated immunity (Zeyda and Stulnig, 2007). This 
leads to the production of TNF-α, IL-6 and IL-1 that contribute to inflammation-related 
comorbidities. In contrast, the M2 state that results in a Th2 response in the alternative 
activation state is pro-fibrotic and promotes the attenuation of the NF-κB signalling 
pathways in cells (Zeyda and Stulnig, 2007). It is associated more frequently with lean 
individuals and is known to offer protection against inflammation. 
Macrophages have also been known to take on adipocyte-like qualities, expressing aP2 
and PPARγ (Charriere et al., 2003). Functionally, both macrophages and adipocytes have 
been shown to exhibit similar qualities too. Adipocytes have been observed to produce 
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inflammatory mediators and participate in the immune response, exhibiting phagocytic 
and anti-microbial activities in some conditions. Preadipocytes may even differentiate 
into macrophages given the right conditions. Macrophages, especially in pro-
atherosclerotic conditions, may accumulate lipids to form foam cells (Wellen and 
Hotamisligil, 2005). 
Other than being secretory entities, macrophages exert an effect on the surrounding 
adipose tissue, causing the adipocytes to respond in a glandular fashion, secreting 
proinflammatory adipokines and acute phase proteins such as TNF-α, IL-6, serum 
amyloid A (SAA), CRP, haptoglobin, MCP-1 and PAI-1 into the systemic circulation 
(Trayhurn and Wood, 2005). CRP is an activator of the complement system and has been 
implicated in ischaemic necrosis. As a result the expression of many complement genes 
have been shown to be upregulated in obesity. SAA can mediate the crosstalk between 
hypertrophied adipocytes and macrophages and PAI-1 directly accelerates the 
development of atherosclerosis (Poitou et al., 2009; Loskutoff and Samad, 1998). MCP-1 
has been known to increase the recruitment and activation of proinflammatory monocytes 
and macrophages (Kanda et al., 2006). 
1.1.4 Adipokines in inflammation 
The subclinical inflammatory state associated with obesity is characterised by chronic 
low-level systemic inflammation in the circulation and in tissues. It is the central 
pathological state by which adipocyte regulatory processes contribute to the development 
of adipose-related comorbidities. The subclinical inflammatory state is characterised by 
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oxidative stress and the elevation of proinflammatory cytokines, such as TNF-α, IL-6, 
PAI-1 and MCP-1 (Fain, 2006). One school of thought attributes this to the increase in 
FFA turnover shown in vitro and in vivo to activate the canonical NF-κB pathway 
(Boden, 2011). Activation of NF-κB and the expression of MCP-1 in particular lead to a 
typical proinflammatory response meant as a protective response for the removal of 
injurious stimuli and cell-mediated immunity. Overstimulation of these inflammatory 
pathways, however, leads to a loss of healthy function in adipose tissue. The chronic low-
grade inflammation associated with obesity has only been recognised fairly recently 
because adipose tissue inflammation seems to lack the classical cardinal signs of 
inflammation - dolor, rubor, calor, tumor and functio laesa (Rather, 1971). Adipose 
tissue is now a known source of TNF-α and IL-6, both mediators of the acute phase 
response (Xu et al., 2003; Fantuzzi, 2005; Trayhurn and Wood, 2005). Increased levels of 
these mediators show molecular participation in the development of metabolic 
dysfunctions, by increasing adipocyte lipolysis and downregulating pro-insulinic 
responses in cells. The initiation of stress-dependent pathways by the influx of excess 
fatty acids and proteins leads to chronic conditions in ER stress and the activation of the 
unfolded-protein-response (UPR) cascade (Hotamisligil, 2010). ER stress reaches a point 
where it can no longer be relieved, UPR causes cell death and these ultimately link to the 
major inflammatory pathways and stress signaling networks such as JNK-AP-1 and Iκκ-
NF-κB pathways which also cause the production of reactive oxygen species. These 
events are highly related to the infiltration of T-cells preceding macrophages and may 
also be crucial to the activation and increased recruitment of macrophages. 
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1.1.5 Dysregulation of adipokines in obesity 
As it is already evident, the high level of coordination and overlapping biology that 
connects inflammatory and metabolic pathways, together with the now apparent co-
localization of the two types of cells, suggests the imperative to shed light on the protein 
signals involved in crosstalk between adipocytes and macrophages. The next few sections 
endeavour to highlight some significant mediators of inflammation produced by adipose 
tissue. 
1.1.5.1 Adiponectin 
Adiponectin is a protein encoded by the ADIPOQ gene (Maeda et al., 1996). It is 
produced almost exclusively by adipocytes. In contrast to the expression of other 
proinflammatory adipokines like TNF-α and IL-6, adiponectin expression is reduced in 
obese, insulin-resistant rodent models (Hu et al., 1996). Thus increasing adiponectin 
levels has been postulated to play a beneficial role in suppressing obesity-linked diseases 
by positively modulating glucose metabolism, increasing insulin sensitivity and glucose 
uptake in cells (Fu et al. 2005). Adiponectin production is known to be upregulated with 
PPARγ activation and known to be inhibited by proinflammatory factors TNF-α and IL-6 
(Berg et al., 2005; Ouchi et al. 2003). Adiponectin-deficient mice were also shown to 
have higher levels of TNF-α mRNA in adipose tissue and TNF-α in the blood and 
administration of recombinant adiponectin showed a restoration of inflammatory 
parameters (Maeda et al., 2002). Adiponectin also exerts other anti-inflammatory effects 
by acting on macrophages and monocytes to inhibit TNF- α and IL-6, as well as increase 
IL-10 and IL-1 receptor antagonist expression. It also shows ability to reduce the 
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induction of the endothelial adhesion molecules ICAM-1 and VCAM-1. Therefore, it 
seems that adiponectin have a protective ability against inflammation via suppression of 
pro-inflammatory cytokine production and may be a candidate gene in reversing 
metabolic dysfunction. 
1.1.5.2 IL-1β 
Interleukin-1 beta (IL-1β) is a cytokine protein that in humans is encoded by the IL1B 
gene. It is involved in acute-phase inflammatory response and like IL-6 it has been shown 
to modulate leptin secretion by adipose tissue in inflammation (Faggioni et al., 1998). It 
has been found recently to modulate glucose metabolism in adipocytes, decreasing 
GLUT-1 and GLUT-4 translocation via the downregulation of IRS-1. IL-1β is therefore 
capable of impairing insulin signaling and action, acting in concert with other cytokines 
in the development of insulin resistance in adipocytes. IL-1β has been shown to 
upregulate the transcription of various inflammation-related genes in adipocytes 
(Permana et al., 2006; Gao and Bing, 2011). 
1.1.5.3 IL-6  
Interleukin-6 (IL-6) is a protein that in humans is encoded by the IL6 gene. IL-6 is 
closely related to TNF-α in its inflammatory effects and its serum levels have been 
reported to be elevated in obesity. It is produced mainly by the stromal-vascular fraction 
of adipose tissue. Although the production of IL-6 has been traditionally associated with 
cells of the immune system, recent studies showed that IL-6 from adipose tissue accounts 
for approximately 30% of circulating levels (Pedersen et al., 2003). IL-6 levels correlate 
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positively with obesity and insulin resistance; high IL-6 levels are predictive of type 2 
diabetes mellitus and  has been shown to modulate insulin action in vivo and in vitro 
(Bastard et al., 2002). It has been suggested that the apparent inhibition of insulin 
receptor signal transduction by IL-6 may be in part due to the increase in suppressor of 
cytokine signalling-3, increased FFA release from adipose tissue and reduced adiponectin 
secretion (Rotter et al., 2003). Long-term exposure of human adipocytes to IL-6 has been 
also shown to induce a decrease in insulin-mediated glucose transport, reducing the 
expression of IRS-1, GLUT-4 and PPARγ (Rotter et al. 2003). An increase in IL-6 levels 
is also known to be responsible for the increase in hypertriglyceridaemia in vivo by 
inhibiting LPL and stimulating lipolysis (Nonogaki et al., 1995; Trujillo et al., 2004). 
1.1.5.4 Leptin 
Leptin is another key adipokine upregulated in obesity (Kettaneh et al., 2007). Leptin is 
essentially thought to play a role in appetite control as a satiety signal in the central 
nervous system. Leptin has been known to be primarily proinflammatory, associating 
with platelet aggregation and arterial thrombosis. As such it has been known to be a good 
predictor of cardiovascular risk and metabolic syndrome. Recent studies also show that 
leptin inhibits the expression of IL-1 receptor antagonist (IL-1Ra), which exerts a 
protective effect on islets from glucose-mediated IL-1 secretion by beta cells. Leptin 
levels are also associated with the inhibition of insulin resistance through the SOC3 gene 
activation and suppression of proinsulin expression through MAPK activation (Seufert, 
2004). While it is an essential hormone for the regulation of appetite and growth of 
adipocyte cells, an overproduction of leptin in obesity has been implicated in the cause of 
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oxidative stress in endothelial cells. This is explained by the accumulation of ROS and 
activation of JAK/STAT pathways by enhanced JNK activity and AP-1 DNA binding. 
Enhancement of NF-κB signalling by leptin also leads to the expression of MCP-1 in 
endothelial cells, increasing the recruitment of monocytes and macrophages to adipose 
tissue. 
1.1.5.5 Monocyte chemoattractant protein-1 (MCP-1) 
MCP-1 (CCL2) is a member of the CC chemokine family. Encoded by the CCL2 gene, 
the main function of MCP-1 is to initiate the diapedesis of monocytes, memory T cells, 
and dendritic cells to sites of injury and inflammation. The main producers of MCP-1 in 
adipose tissue are preadipocytes, adipocytes and resident mononuclear cells. Its 
expression is upregulated with obesity, making MCP-1 is a key candidate gene for the 
modulation of macrophage infiltration in obese adipose tissue. This has been supported 
by studies where MCP-1 and its receptor (CCR2) knockdown studies in animals 
presented a significant reduction of macrophages, decreased inflammatory mediators and 
greater insulin sensitivity (Kanda et al., 2006; Weisberg et al., 2006). 
1.1.5.6 TNF-α 
TNF-α is a cytokine involved in systemic inflammation and the acute phase reaction. 
Expression of TNF-α in adipose tissue is elevated in a variety of experimental obesity 
models (Hotamisligil et al., 1993; Hofmann et al., 1994; Hamann et al., 1995). Recent 
data have suggested a key role for TNF-α in the inflammatory pathogenesis of insulin 
resistance in obesity and non-insulin dependent diabetes mellitus by blocking the action 
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of insulin by inhibiting insulin receptor tyrosine kinase activity. TNF-α has been shown 
to induce SOCS-3 (suppressor of cytokine signalling-3), an intracellular signalling 
molecule that impairs leptin and also IRS-1 and IRS-2, PI3-K and insulin-stimulated 
glucose uptake. It also activates NF-κB, which forms the basis for its proatherogenic 
qualities. As majority of the TNF-α is produced by infiltrated macrophages, the increase 
in macrophage infiltration in obesity explicates the upregulation of serum TNF-α levels 
observed in obesity-linked inflammatory comorbidities. 
1.1.5.7 Zinc-α2-glycoprotein (ZAG) 
Zinc-α2-glycoprotein, a soluble protein of approximately 41 kDa, is also another known 
adipokine. Although the exact role of this novel adipokine has yet to be elucidated, ZAG 
appears to be increased in cancer cachexia (Bing et al., 2004) and decreased in obesity. 
Zinc-alpha2-glycoprotein (ZAG) has been also found to play a role in adipose tissue 
lipolysis and has been proposed to be a candidate gene in body weight regulation (Gong 
et al., 2009). Recent work by the department demonstrated that ZAG was able to increase 
adiponectin release by human adipocytes at physiologically relevant levels (Mracek et 
al., 2010). The finding suggests a possible paracrinic action of ZAG to stimulate 
adiponectin secretion in adipocytes, which is an anti-inflammatory adipokine known to 
exert beneficial effects on insulin sensitivity and inflammation. 
1.1.6 The adipocyte as a model system 
It is understood that adipocytes and macrophages play essential roles in the formation of 
an inflammatory state by inter-potentiating each others’ effects, often leading to excess 
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inflammation in obesity. Therefore it is essential that the web of interaction must be 
dissected to understand their individual roles so as to facilitate research into disease 
amelioration. Adipocyte response has been identified to be the focal point of this thesis as 
1) They have physically important secretory functions 2) They are proactive in their 
nature, responding well to stimuli 3) The current belief that adipocytes cause the principle 
release of the initial errant signal (i.e. excessive production of leptin) in hypertrophy. 
Errant signalling of leptin is postulated to exert paracrine effects on the endothelial cells, 
including the accumulation of ROS, activation of JAK/STAT pathways and enhancement 
of NF-κB signalling, leading to enhanced recruitment of mononuclear cells which 
eventually ignites a proinflammatory cycle (Fantuzzi, 2005). 
Adipocytes also have a unique secretory genotype with quiescent genes that once 
activated by a suitable environment, allows them to take on macrophage-like qualities. 
This is evidenced by the observed cellular plasticity of adipocyte precursors when 
injected into the peritoneal cavity; preadipocytes morphed into cells exhibiting high 
phagocyte activity and expressed five markers specific to macrophages: F4/80, Mac-1, 
CD80, CD86, and CD45 (Charrière et al., 2003). As a result, adipocytes have been shown 
to exhibit macrophage-like qualities in obesity, producing increased levels of 
proinflammatory cytokines TNF-α, IL-6 and MMPs (matrix metalloproteinases). TNF-α 
and IL-6 have been shown to induce SOCS-3, an intracellular signalling molecule that 
impairs leptin and also IRS-1 (Insulin receptor substrate-1), IRS-2 (Insulin receptor 
substrate 2), PI3-K and insulin-stimulated glucose uptake (Cawthorn and Sethi, 2008). 
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It has also been suggested that adipocyte hypertrophy leads to increased macrophage 
recruitment to adipose tissue (Xu et al., 2003). This increased presence of macrophages 
observed in the late stages of obesity has garnered great interest of late as macrophage 
infiltration may potentially establish the link between inflammation and obesity. A local 
paracrine inflammatory loop is induced by FFAs produced by hypertrophied adipocytes 
and macrophage-produced factors, particularly TNF-α (Suganami et al., 2005). Studies 
have shown that FFAs produced by hypertrophied adipocytes bind toll-like receptor-4 
(TLR-4) leading to the activation of NF-κB resulting in the increased production of TNF-
α and subsequent proinflammatory cytokines such as IL-6, MCP-1, intracellular adhesion 
molecule-1 (ICAM-1) and iNOS (Suganami et al., 2007; Yeop Han et al., 2010). The 
release of these factors into the SVF and resultant release into the circulation may, as 
such, explain the chronic systemic inflammation associated with obesity. 
An appropriate adipocyte model in an inflammatory environment would therefore be 
essential in understanding the crosstalk that occurs in obesity. The additional advantage 
of this model is the opportunity to study restorative agents. Agents such as adiponectin 
and siRNAs (Diez and Iglesias, 2003; Aouadi et al., 2009) have been identified and 
studied in rodent models to mitigate the adverse effects of excessive inflammation 
associated with obesity. A potential agent that we aim to investigate in this study is 
vitamin D. The next chapter illustrates its emergence as an immune system modulator. 
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1.2 The Vitamin D System 
Vitamin D deficiency has been extensively linked to an increased risk of developing 
insulin resistance and metabolic syndrome (Isaia et al., 2001; Chiu et al., 2004; Martini et 
al., 2006). Hypovitaminosis D is re-emerging as a global health problem, coinciding with 
the doubling of official numbers of diabetic patients over the last three decades and the 
exponential increase in obese persons globally. The first official medical treatise on 
vitamin D deficiency came with the discovery of childhood rickets. Published by Francis 
Glisson in the 1650s, the disease was more commonly associated with the rich rather than 
poorer communities in society. Sniadecki was the first to recognise in 1822 that the 
development of rickets was due to a lack of sunlight exposure. By the mid-1800s cod 
liver oil was established as an effective remedy for rickets and it was later found that 
vitamin D was the agent in cod liver oil that gave it its anti-rachitic properties. 
Today vitamin D has been shown to produce potential nonskeletal benefits in a variety of 
clinical outcomes, including mortality, diabetes mellitus, cardiovascular disease, cancer, 
multiple sclerosis, asthma, sepsis, depression and pain. History suggests that the re-
emergence of vitamin D deficiency could be due to rising affluence, leading to increased 
sedentary lifestyles, lack of outdoor activity, ease of access to a convenience foods diet 
and obesity. Obesity, in particular, has been shown to be a single, independent risk factor 
for vitamin D deficiency (Snijder et al., 2005). Decreased circulating levels of 25-
hydroxyvitamin D3, a predictor of vitamin D status, have also been found to be a 
correlating predictor of obesity. It has been proposed that increased adiposity results in 
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the enhanced storage of vitamin D in adipocytes, leading to decreased circulating levels 
of vitamin D. The hormone leptin, whose circulating levels increase proportionately to 
adiposity, has also been shown to lower renal CYP27B1 gene expression, suggesting a 
decreased bioavailability of vitamin D in obesity (Matsunuma and Horiuchi, 2007). As 
such, clinicians have suggested that an increased supplementation of vitamin D is 
required for persons with a higher body fat percentage. Adiposity is an important 
determinant of assayed 25-hydroxyvitamin D levels and has been implicated as a cause 
for the prevailing association of low vitamin D status with obesity-linked disease 
outcomes, including metabolic syndrome and congestive heart failure. Multiple lines of 
evidence also now suggest that vitamin D also plays a role in glucose homeostasis in 
cells; among its modes of action are increasing transcription of the insulin receptor gene, 
activating PPAR-δ and enhancing insulin-mediated glucose transport in vitro (Maestro et 
al., 2000, 2002; Dunlop et al., 2005). 
1.2.1 Calcitriol, VDR and the function of VDR in signalling and transcription 
Calcitriol is the active form of vitamin D3 utilised by the body. Otherwise known as 1,25-
dihydroxycholecalciferol or 1,25-dihydroxyvitamin D3, calcitriol is a seco-steroid in 
which the B-ring of the cyclopentanoperhydrophenanthrene structure is cleaved (Walters, 
1992). It is formed through the conversion of 25-hydroxyvitamin D3, an inactive 
hormonal precursor of calcitriol, by the enzyme CYP27B1 or 1α-hydroxylase which is 
found primarily in the kidney. Vitamin D3 and its metabolites are primarily found in 
association with vitamin D-binding globulin, a 50-kDa protein found in the blood. The 
level of 25-hydroxyvitamin D in the body is determined by the intake of dietary vitamin 
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D or synthesis in the skin. Pre-vitamin D can be synthesised from 7-dehydrocholesterol 
by ultraviolet B radiation during exposure to the sun. 1α-hydroxylase activity is 
controlled by ionic and endocrine factors such as PTH and plasma calcium, and is 
inhibited by calcitriol through a negative feedback loop mechanism (Jones et al., 1998). 
Interestingly, significant extrarenal sources 1α-hydroxylase suggest a possibility of 
higher local tissue concentrations of calcitriol and a possible autocrine/paracrine role of 
1,25-dihydroxyvitamin D3 (Jones et al., 1998; Zehnder et al., 2001). 
The seco-steroid is the natural ligand for the vitamin D receptor (VDR), a ligand-
activated nuclear transcription factor and a member of the steroid-thyroid-retinoid 
receptor gene superfamily (Mangelsdorf et al., 1995). Receptors of the steroid-thyroid-
retinoid receptor gene superfamily have a highly conserved DNA-binding domain (DBD) 
and a more variable Ligand-binding domain (LBD). The human VDR consists of 427 
amino acids and has a molecular mass of about 48 kDa. Its main components consist of 
the A/B region, the DBD, the LBD and a transactivation AF-2 region (Issa et al., 1998). 
The A/B region of the VDR consists of a truncated domain lacking the usual AF-1 
transactivation function of nuclear hormone receptors, suggesting that this domain has 
little or no function in the VDR. Studies have also shown that the removal of the region 
does not seem to affect DNA binding, ligand binding or its transactivation properties 
(Issa et al., 1998).  
The VDR DBD is located between amino acids 24 and 90. It contains nine highly 
conserved cysteine residues that enable the DBD to fold into two loops of 12-13 amino 
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acids each (Malloy et al., 1999). Each loop contains 4 cysteine residues that enables the 
binding of a zinc atom, yielding a two “zinc-finger” structure. In the amino-terminal zinc 
finger loop, an α-helical P-box makes contact with specific nucleotide bases in the major 
groove of the DNA-binding site. At the carboxyl-terminal zinc finger module, two α-
helices form the D and T-boxes. The D-box appears to participate in DNA binding, 
serving as a dimerization interface for interaction with a partner protein. The T-box has 
been shown to provide key interactions with partner proteins, making minor groove 
contacts with nucleotides located between two DNA half-sites, enhancing the interaction 
of the VDR with the DNA-binding elements and thus the heterodimerization with the 
Retinoid X receptor (RXR). 
The D region that follows the DBD, also termed a hinge region, displays a site for serine 
phosphorylation which suggests additional functional roles of the hinge region - although 
this has not been clearly defined (Issa et al., 1998). The hinge region has been known to 
facilitate nuclear transfer of the receptor. The LBD of VDR is multifunctional and serves 
three main purposes: binding of the calcitriol ligand, hetero- or homodimerization and 
recruitment of regulatory factors required for transcriptional activation (Issa et al., 1998). 
The structural arrangement of the VDR LBD is complex and stretches over two-thirds of 
the protein. The VDR LBD is made up of 12 α-helices (H1 to H12) and 1 β-sheet. Its 
three-dimensional structure suggests that conserved residues in a 34-amino acid cluster 
form a hydrophobic core by holding together a series of α-helices and loops while 
another series of α-helices and loops form a three-dimenstional pocket as an occupation 
site for the ligand. The α-helices H11 and H12 are thought to function together as a 
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‘retractable lid’ that serves to trap and hold the ligand in position. The 1α-hydroxyl group 
forms a hydrogen bond with Ser237 and Arg274 found lining the LBD and the 3-OH 
moiety forms a hydrogen bond with Ser278 and Tyr143. The 25-hydroxyl group forms 
hydrogen bonds with His305 and His397. 
Upon binding of the ligand, VDR undergoes a conformational change that facilitates its 
dimerization with RXR, as well as its binding to DNA and coactivators. The AF-2 
domain, encompassing the H12 helix and the E1 region (between amino acids 232 and 
272) are essential for transactivation (Malloy et al., 1999). Once the nuclear VDR 
heterodimerises with the RXR it binds to vitamin D response elements (VDREs) in the 
promoter region of target genes. The binding of the heterodimer to the VDRE results in a 
concomitant recruitment of co-activator proteins that form multi-protein complexes that 
together with basal transcriptional machinery and histone modifiers, stimulate 
transcription of genes with VDREs. In addition, many heterogeneous target genes for the 
VDR have been identified, reflecting the vast continuum of gene expression regulatory 
activity modulated by calcitriol (Carlberg, 2003). Calcitriol has also been known to 
associate with vitamin D membrane-associated rapid response steroid hormone binding 
protein (1,25-MARRS) which can stimulate rapid changes in the plasma membrane, 
possibly playing a role in Ca2+ signalling and homeostasis within the cell (Khanal and 
Namere, 2007). 
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1.2.2 Immunomodulating effects of vitamin D or VDR activation 
Until much recently, calcitriol has been increasingly recognised as a potent 
immunomodulating agent. Besides its topical use in the treatment in psoriasis, calcitriol 
has been shown in experimental studies to inhibit the production of IL-2, IL-6, IFN-γ and 
GM-CSF in peripheral blood mononuclear cells (Inoue et al., 1998). Calcitriol has also 
been shown to inhibit the development of immune diseases and particularly effective in 
inflammatory bowel disease. Microarray studies of the colons of calcitriol-treated mice 
showed an inhibition of TNF-α, LPS-induced TNF-α factor and TNF-α receptor. Vitamin 
D supplementation also resulted in lower TNF-α concentrations in patients with 
congestive heart failure (Schleithoff et al., 2006). It has been known to exert specific 
effects on monocytes, T-cells and antigen-presenting cells such as macrophages, dendritic 
cells, lowering IL-1 through 6 and IFN-γ (Lin and White, 2004; Haussler et al., 1998). 
There is a considerable amount of evidence that shows vitamin D has a significant effect 
on the enhancement of immune system function as well as the inhibition of autoimmunity 
development. 
The effects of calcitriol, however, have not been studied extensively in adipocytes. 
Studies done on 3T3-L1 adipocytes by Sun and Zemel (2008) revealed that calcitriol up-
regulated macrophage colony-stimulating factor, macrophage inflammatory protein, IL-6 
as well as MCP-1 expression. However on examination of presented data it seemed that 
anti-inflammatory cytokine expression had also increased. Anti-inflammatory cytokine 
production was neither highlighted in the paper, nor was it discussed. This is particularly 
important as it could suggest the adipocyte’s immunoregulatory role – possibly playing a 
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role in attenuating macrophage and monocyte activity in the course of their localization. 
IL-4 and IL-13 are known to inhibit proinflammatory cytokine production, attenuate 
monocyte/macrophage function and promote Th2 helper cell proliferation. It was also not 
established whether the source of the cytokine production in the co-culture study was the 
macrophages or adipocytes. The calcitriol-mediated upregulation of IL-10 could also 
present potential benefits. Hong et al. (2009)  demonstrated that IL-10 increased insulin 
sensitivity, protected from obesity-induced macrophage infiltration and protects against 
the deleterious effects of proinflammatory cytokines on insulin signalling. IL-6 seems to 
exhibit an equivocal effect, exhibiting both proinflammatory and anti-inflammatory 
effects. In particular, IL-6 inhibits TNF-α and IL-1 production by macrophages (Opal and 
DePalo, 2000). Calcitriol also exerted an anti-inflammatory effect on 3T3-L1 adipocytes, 
reducing IL-6 without reducing IL-10 when supplemented together with vitamin E (Lira 
et al., 2011). 
1.2.3 Vitamin D and obesity 
Studies suggest that plasma concentrations of vitamin D are lowered in obesity (Parikh, 
2004; Hultin 2010).  Hyppönen (2007) described vitamin D levels as being lower in 
obese persons compared to lean individuals in a major cohort study. Although it was 
postulated to be due to the tendency of obese persons to spend time indoors and a 
decreased inclination to sun exposure, the global incidence of vitamin D deficiency 
suggests that the amount of UV exposure may only represent one causal link. In addition 
to epidemiological links of insulin resistance to vitamin D deficiency, vitamin D was also 
recently associated with metabolic syndrome in morbid obesity, showing a positive 
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correlation with serum triglyceride concentration (Botella-Carretero et al., 2007). With 
vitamin D and adiposity both showing converging links to the same comorbidities, there 
now lies considerable impetus to determine the exact effects of vitamin D on adipose 
tissue biology.  
  
32 
 
1.3 Aims of the study 
Based on recent studies it is understood that macrophage infiltration in adipose tissue has 
a complex and manifold effect in physiology, especially in its upregulation in obesity and 
the pathogenesis of its comorbidities. Crosstalk of macrophages with adipocytes has been 
hypothesised to induce the observed increase in macrophage infiltration and 
inflammatory response in obese WAT. Macrophage-derived cytokines have been 
observed to exert an array of physiological effects on various tissues and organs via the 
components of the immune system, many of which have known links to metabolic 
diseases. A better understanding of adipocyte response in an inflammatory environment 
may help to develop better treatment strategies for obesity and its consequent 
comorbidities. 
Given the limited amount of research conducted on the effects of calcitriol on 
macrophage and adipocyte crosstalk, the initial aim of this study is to investigate the 
effects of macrophage-derived factors on the inflammatory responses of human primary 
adipocytes. After which, a proposed role for calcitriol in the reversal of inflammatory 
responses in adipocytes is investigated. 
The working hypothesis is that calcitriol treatment ameliorates inflammation through 
modulating the expression and secretion of inflammatory mediators by adipocytes. 
Therefore, the specific aims of this study are to: 
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1. Establish an in vitro inflammatory environment for adipose cells by exposure of 
adipocytes to macrophage-conditioned medium. 
2. Determine gene expression and protein release of inflammatory mediators by 
adipocytes stimulated with macrophage-derived factors. 
3. Study the signalling pathways that are involved in macrophage-induced 
inflammatory response in adipocytes. 
4. Examine the effects of vitamin D supplementation on crosstalk between 
adipocytes and macrophages. 
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Chapter 2  
Materials and methods 
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2.1 Reagents and equipment 
Table 2.1 Chemical reagents 
Reagents Supplier 
Pure ethanol Sigma 
1-α, 25-Dihydroxyvitamin D3 Enzo Life Sciences 
β-Mercaptoethanol SERVA 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) 
Sigma 
3-isobutyl-1-methylxanthine (IBMX) Sigma 
Acrylamide/Bisacrylamide Bio-rad 
Ammonium persulphate Bio-rad 
Anti-α-Tubulin mouse mAb Sigma 
Bicinchoninic acid Sigma 
Biotin Sigma 
Bisacrylamide Bio-Rad 
Bovine Serum Albumin Sigma 
Bromophenol blue Sigma 
Chloroform Fisher Scientific 
Coomassie Brilliant Blue dye Fisher Scientific 
Copper sulphate Sigma 
Dexamethasone Sigma 
Dulbecco's Modified Eagle's Medium/Ham's Nutrient 
Mixture F12 
Sigma 
Fetal Calf Serum Sigma 
Glycerol Sigma 
Glycine Sigma 
Hydrochloric acid Fisher Scientific 
Insulin Sigma 
Isopropanol Sigma 
Human IκBα Mouse mAb New England Biolabs 
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L-Thyroxine Sigma 
Methanol Fisher Scientific 
PageRuler prestained protein ladder Fermentas 
Penicillin/Streptomycin mix Sigma 
Penicillin/Streptomycin/Fungizone mix Sigma 
Phorbol-12-myristate-13-acetate Sigma 
Phosphate-buffered saline tablets Sigma 
Phospho p38 MAPK Rabbit mAb New England Biolabs 
Phospho-NF-κB p65 Rabbit mAb New England Biolabs 
Phospho-p44/42 MAPK Rabbit mAb New England Biolabs 
Ponceau S Sigma 
Protease inhibitor cocktail Sigma 
Phosphatase inhibitor cocktail Sigma 
RNase AWAY Molecular BioProducts, Inc. 
Rosiglitazone Enzo Life Sciences 
Roswell Park Memorial Institute medium (RPMI-1640) Sigma 
Skimmed milk powder Lidl 
Sodium dodecyl sulphate Sigma 
Sodium Chloride Sigma 
SYBR Green I dye Eurogentec 
SYBR Green primers Sigma 
Taqman primers Eurogentec 
Taqman probes Eurogentec 
Tetramethylethylenediamine (TEMED) Sigma 
TNF-α Sigma 
Total Akt Rabbit antibody New England Biolabs 
Tricine Sigma 
Trizma BASE Sigma 
TRIzol ® reagent Sigma 
Trypsin-EDTA solution Sigma 
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Water, molecular biology reagent (DEPC-treated, ultra-
pure water) 
Sigma 
 
Table 2.2 Commercial kits 
Kits Supplier 
Cytotoxicity Detection Kit Roche 
Free glycerol determination kit Sigma 
Human adiponectin DuoSet® ELISA development 
system 
R & D Systems 
Human IL-1β DuoSet® ELISA development system R & D Systems 
Human IL-6 DuoSet® ELISA development system R & D Systems 
Human MCP-1 DuoSet® ELISA development system R & D Systems 
Human Zinc-alpha-2-glycoprotein ELISA BioVendor 
iScript cDNA synthesis kit Bio-rad 
qPCR Core kit Eurogentec 
SuperSignal® West Pico ECL kit Thermo Scientific 
 
Table 2.3 Equipment 
Equipment Supplier 
12/24 well tissue culture plates Techno Plastic Products 
96-well real time PCR plates Starlab 
BenchmarkTM Plus Microplate Spectrophotometer Bio-Rad 
Bio-Rad Mini-PROTEANTM Tetra Electrophoresis 
System 
Bio-Rad 
Biophotometer Eppendorf 
Bottle top 0.2 µm filters Techno Plastic Products 
ChemiDoc™ XRS+ System Bio-Rad 
Disposable serological pipette tips Starlab 
Hybridizer hybridization oven UVP 
LABNET Multigene Gradient thermal cycler Labnet International 
Mx3005P QPCR system Stratagene (Agilent) 
Nikon Diaphot inverted microscope/D50 camera Nikon 
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Nunc MaxiSorp® flat-bottom 96 well plate Thermo Scientific 
Hybond ECL nitrocellulose membrane Amersham 
Real-time PCR Sealing Film Elkay 
Refrigerated microcentrifuge Eppendorf 
Syringe 0.2 µm filters Techno Plastic Products 
UVette plastic disposable cuvettes Eppendorf 
 
Table 2.4 Software 
Software Supplier 
Camera Control Pro Nikon 
Graphpad Prism Software GraphPad Software, Inc. 
Image LabTM image acquisition and analysis software Bio-Rad 
Microplate Manager 5.2 Bio-Rad 
MxPro QPCR software Stratagene 
SPSS (PASW) v18.0.0 IBM 
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Table 2.5 Suppliers’ addresses and URLs 
Company Address and URLs 
Amersham 
Amersham Pl, Little Chalfont,  Buckinghamshire, United Kingdom, Tel: 
[44] 0870 606 1921. http://www.amershambiosciences.com 
Bio-Rad 
Bio-Rad Laboratories Ltd, Bio-Rad House. Maxted Road, Hemel 
Hempstead, Hertfordshire HP2 7DX, United Kingdom. http://www.bio-
rad.com 
BioVendor 
BioVender GmBH, Im Neuenheimer Feld 583, D-69120 Heidelberg, 
Germany. http://www.biovendor.com 
Elkay 
Elkay Laboratory Products (UK) Limited, Unit E, Lutyens Industrial 
Centre, Bilton Road, Basingstoke, Hampshire RG24 8LJ, United 
Kingdom. http://www.elkay-uk.co.uk 
Enzo Life Sciences 
Enzo Life Sciences (UK) LTD, Palatine House , Matford Court, Exeter 
EX2 8NL, United Kingdom. http://www.enzolifesciences.com 
Eppendorf 
Eppendorf UK Limited, Endurance House, Vision Park, Chivers Way, 
Histon, Cambridge CB24 9ZR, United Kingdom. 
http://www.eppendorf.co.uk 
Eurogentec 
Eurogentec Ltd. Old Headmasters House, Unit 1, Building 1, Forest 
Business Centre, Fawley Road, Fawley, Southampton, Hampshire SO45 
1FJ, United Kingdom. http://www.eurogentec.com 
Fermentas 
European Head Office Germany. Fermentas GmbH, Opelstrasse 9, 
68789 St. Leon-Rot, Germany. http://www.fermentas.de 
Fisher Scientific 
Fisher Scientific UK Ltd. Bishop Meadow Road, Loughborough, 
Leicestershire, LE11 5RG, United Kingdom. http://www.fisher.co.uk 
GraphPad 
Software, Inc. 
GraphPad Software, Inc. 2236 Avenida de la Playa, La Jolla, CA 92037, 
USA. http://www.graphpad.com 
IBM SPSS 
2 New Square, Bedfont Lakes, Feltham, Middlesex TW14 8HB, United 
Kingdom. http://www-01.ibm.com/software/uk/analytics/spss/ 
Labnet 
International 
Labnet International. PO Box 841, Woodbridge, NJ 07095, USA. 
http://www.labnet.com 
Molecular 
BioProducts, Inc. 
Molecular BioProducts, Inc. B399389 Waples Street, San Diego, CA 
92121-3903. http://www.mbpinc.com 
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New England 
Biolabs 
New England Biolabs (UK) Ltd. 75/77 Knowl Piece, Wilbury Way, 
Hitchin, Herts. SG4 0TY, United Kingdom. http://www.neb.com 
Nikon 
Nikon UK Limited. 380 Richmond Road, Kingston upon Thames, 
Surrey KT2 5PR, United Kingdom. http://www.europe-nikon.com 
R & D Systems 
R&D Systems Europe Ltd. 19 Barton Lane, Abingdon Science Park, 
Abingdon, OX14 3NB, United Kingdom. http://www.rndsystems.com 
Roche 
Roche Diagnostics Limited. Charles Avenue, Burgess Hill, West Sussex 
RH15 9RY. United Kingdom. http://www.rocheuk.com 
SERVA 
SERVA Electrophoresis GmbH. Carl-Benz-Str. 7 P.O.B. 10 52 60, 
69115 Heidelberg, Germany. http://www.serva.de 
Sigma 
Sigma-Aldrich Company Ltd. Fancy Road, Poole, Dorset BH12 4QH, 
United Kingdom. http://www.sigmaaldrich.com/united-kingdom.html 
Starlab 
STARLAB (UK), Ltd. Unit 4 Tanners Drive, Blakelands, Milton 
Keynes MK14 5NA, United Kingdom. http://www.starlab.de 
Stratagene (Agilent) 
Agilent Technologies, Inc. Life Sciences and Chemical Analysis, Group 
5301, Stevens Creek Boulevard, Santa Clara, CA 95051-7201, USA 
Techno Plastic 
Products 
TPP Techno Plastic Products AG, Zollstrasse 155, CH-8219, 
Trasadingen, Switzerland 
Thermo Scientific 
Thermo Fisher Scientific Inc. Unit 9 Altey Way North Nelson Industrial 
Estate Cramlington, Northumberland, NE23 1WA. 
http://www.thermoscientific.com 
UVP 
Ultra-Violet Products Ltd, Unit 1, Trinity Hall Farm Estate, Nuffield 
Road, Cambridge CB4 1TG, United Kingdom. http://www.uvp.com 
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2.2 Cell culture 
For THP-1 and human primary adipocyte cell culture, all precautions were taken to 
prevent any contamination of the cells. All glassware was autoclaved and sterile plastic 
ware was used. The UV-C lamp in the laminar flow cabinet or tissue culture hood was 
switched on to sterilise the shell for 20 minutes and wiped with 1% Vircon solution 
followed by 70% ethanol prior to use. The laminar flow cabinet was allowed to run for 15 
minutes prior to use. All bottles and universals were opened within a sterile tissue culture 
hood. Media components were pipetted using single-use serological pipette tips (Starlab, 
Milton Keynes, UK) and filtered through a 0.22 µm filter membrane (Techno Plastic 
Products, Trasadingen, Switzerland). Prepared media were kept at 4°C for a maximum of 
2 weeks if required later for experiments and pre-warmed at 37°C in a HB-1000 
hybridization oven (UVP, Cambridge, UK) before usage. 
2.2.1 THP-1 monocytes culture and preparation of macrophage-conditioned 
medium 
2.2.1.1 Human THP-1 cell culture medium 
Reagents and equipment 
1 x Roswell Park Memorial Institute 1640 medium 
10% foetal calf serum 
100 U/ ml penicillin and 100 µg/ ml streptomycin mix 
75cm2 cell culture flasks 
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Pipette and sterile pipette tips 
50ml centrifuge tubes 
100 nM phorbol 12-myristate 13-acetate (PMA) 
2.2.1.2 Human monocytes 
The human THP-1 acute monocytic leukaemia cell line was kindly provided by Professor 
Helen R Griffiths (Aston University, UK). Vials of cells were stored in liquid nitrogen 
until the day of subculture. 
2.2.1.3 Cell generation and maintenance 
A frozen vial of aliquoted human THP-1 monocytes (1×106 cells/ml) was removed from 
liquid nitrogen storage and defrosted in a water bath at 37°C. Cells were cultured in 24-
well plates at 37°C. 1 ml of pre-warmed human THP-1 cell culture medium was added to 
the aliquot to help defrosting and gentle pipetting was performed to aid with the thawing. 
The thawed aliquot was then added to a 75 cm2 flask with 25ml of THP-1 cell culture 
medium and incubated at 37°C for 24 hours in a humidified atmosphere of 5% CO2 / 95% 
air. The cells were extracted and spun down at 249 x g for 5 minutes, the supernatant was 
removed and the cells were reconstituted with 5 ml of fresh cell culture media. The 
reconstituted cells were dispensed into a 75 cm2 cell culture flask and 25 ml of culture 
media was added to the flask. Cells were passaged every 3 – 4 days when cell density 
reached 106 /ml. 
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2.2.1.4 Differentiation of THP-1 cells and preparation of macrophage-conditioned 
medium 
For the preparation of macrophage-conditioned (MC) medium, THP-1 monocytes were 
differentiated by the addition of 100 nM PMA (Sigma) for 48 h and then replaced with 
serum-free RPMI-1640 medium (without PMA) for 24 h to a cell density of 106 /ml. The 
MC medium was then collected and stored at -80°C until required. 
2.2.2 Culture and differentiation of human preadipocytes 
2.2.2.1 Reagents 
Human preadipocyte subculture medium 
1 x Promocell preadipocyte growth medium 
1 x Promocell preadipocyte supplement mix 
100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B mix 
Human preadipocyte differentiation medium 
1 x Dulbecco's Modified Eagle's Medium-Ham’s F-12 (1:1, vol/vol) 
Biotin 32 µM 
Insulin 100 nM 
Dexamethasone 1µM 
3-isobutyl-1-methylxanthine 200 µM 
L-Thyroxine 11 nM 
Rosiglitazone 8 µM 
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Human primary adipocyte maintenance medium 
1 x Dulbecco's Modified Eagle's Medium-Ham’s F-12 (1:1, vol/vol) 
3 % foetal calf serum 
100 nM insulin 
32 µM biotin 
1 µM dexamethasone 
100 U/ml penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B mix 
Cell culture reagents 
Trypsin-EDTA solution (0.05% / 0.02%) 
Autoclaved phosphate-buffered saline 
2.2.2.2 Human preadipocyte storage 
Human white preadipocytes used in the experiments were derived from subcutaneous 
adipose tissue of a female Caucasian subject (BMI 21; age 44 years) and were obtained 
from PromoCell (Heidelberg, Germany). Aliquots were stored in liquid nitrogen until 
required. 
2.2.2.3 Resuspending preadipocytes from cryopreservation 
Preadipocytes were resuspended and cultured according to the protocol provided by 
Promocell (Heidelberg, Germany). Preadipocyte aliquots were removed from liquid 
nitrogen and immediately submerged in 37°C water bath for 90 seconds. 20 ml of 
preadipocyte growth medium was added to a 150 cm2 cell culture flask. Cells were 
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resuspended in 5 ml of growth medium and the contents pipetted into the flask. Flasks 
were incubated at 37°C in a humidified atmosphere of 5% CO2 / 95% air for 24 hours. 
Cells were then removed from incubation and checked for viability under a phase 
contrast Diaphot inverted microscope (Nikon, Surrey, UK). The cell culture was then 
decanted into a 50 ml centrifuge tube and centrifuged at 249 x g for 5 minutes. Cells were 
resuspended and incubated for 3 to 4 days to 70% confluency to ensure cells do not 
undergo growth arrest at 100% confluence. 
2.2.2.4 Preadipocyte subculture 
Preadipocytes were observed under the phase contrast microscope to ensure 
approximately 70% confluency. The spent medium was aseptically removed and cell 
monolayer was washed twice with phosphate-buffered saline (PBS) by streaming the 
saline from the non-coated side of the flask and swirling the flask. The PBS was aspirated 
after each washing step. 3 ml of trypsin solution was added to the flask and left at room 
temperature for 5 minutes to dislodge adhered cells. The cells were observed under the 
microscope for roundness of cells and >90% detachment. When cells were sufficiently 
detached, 4 ml of preadipocyte growth medium was added to the flask and swirled to 
neutralise the trypsin solution. An aliquot of the flask contents was obtained for cell 
count and the remaining was decanted into a 15 ml centrifuge tube. Cells were counted 
using a haemocytometer to obtain approximate total number of cells. The total number of 
cells was divided accordingly to calculate the cell suspension volume required to obtain a 
cell plating density of 40,000 cells per millilitre/well. The cells were spun at 249 x g for 5 
minutes. The supernatant was then aspirated from the tube and resuspended first in 5ml 
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of preadipocyte growth medium to ensure homogeneity, then added to the rest of the 
resuspension volume. The flask was swirled to ensure further homogeneity. 1 ml of cell 
suspension was dispensed into each well. The cells were incubated for 3 to 4 days to 
confluence. 
2.2.2.5 Preadipocyte differentiation 
At confluence, cells were induced to differentiate at day 0 by incubation for 3 days in 
human preadipocyte differentiation medium. After induction, cells were further 
maintained in maintenance medium containing 3 % FCS, 100 nM insulin, 32 µM biotin 
and 1 µM dexamethasone until full differentiation into adipocytes which was verified by 
the phase contrast microscopy of lipid droplets accumulated intracellularly using a 
Diaphot inverted microscope (Nikon, Surrey, UK). 
2.3 Cell Culture Treatment 
2.3.1 Macrophage-induced inflammation in adipocytes 
To examine the effect of a moderate inflammatory environment on human primary 
adipocytes, 25% MC medium was prepared by mixing MC medium and maintenance 
medium in the ratio 1:3. A control medium containing 25% RPMI-1640 medium was also 
prepared concurrently by mixing RPMI medium with maintenance medium in the ratio 
1:3. Each mixture was subsequently filtered through a 0.22 µm filter prior to use for the 
treatment of cells. The maintenance medium in wells of confluent cells were aspirated 
and replenished every three days. Fresh maintenance medium was replenished on day 11.  
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The maintenance medium was aspirated on day 13 and incubated in 25% MC medium. 
Control cells were incubated in 25% RPMI medium. The medium, cell lysates and 
TRIzol® extracts (section 2.5 and 2.7) were collected after 24 or 48 hours. 
2.3.2 Effects of vitamin D on macrophage-induced inflammatory response in 
adipocytes 
To study adipocytes’ behaviour to calcitriol treatment, 1 mg/ml calcitriol stock solution 
(Enzo, USA) was diluted in DMSO (0.22 µm filtered) and added to maintenance medium 
to produce medium of varying calcitriol concentrations (10-8M and 10-11M) for dose-
response study. Groups of cells were then treated with calcitriol-supplemented medium at 
each concentration on day 11 post-confluence. A separate group of cells was replenished 
with maintenance medium on day 11 as a control. Wells were incubated for 48 hours 
prior to inflammatory stimulation. Calcitriol was added to 25% RPMI and 25% MC 
medium to produce medium with varying calcitriol concentrations (10-8M and 10-11M). 
The maintenance medium was aspirated from the wells on day 13 and treated with 
corresponding calcitriol concentrations in 25% RPMI or 25% MC. Cells used for the 
study of inflammatory stimulus on adipocytes were used as a control for this study. The 
cells were incubated for 24 or 48 hours at 37°C in a humidified atmosphere of 5% CO2 
and 95% air. 
2.3.3 Effect of vitamin D on TNF-α induced inflammatory response in adipocytes 
To study the effect of TNF-α on adipocytes, cells were treated with maintenance medium 
with varying calcitriol concentrations (10-8M and 10-11M) or maintenance medium 
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without calcitriol supplementation on day 11 post-confluence for 48 hours. Cells were 
then treated on day 13 with 5ng/ml human recombinant TNF-α (Sigma, Poole, UK) in 
25% RPMI medium either supplemented with calcitriol at varying concentrations or 
without supplementation. Cell and medium collection was performed on day 15. 
2.4 Cell and media collection 
For cell and media collection from cell cultures, all precautions were taken to prevent any 
contamination of the cells and medium. All glassware was autoclaved and sterile plastic 
ware was used. The UV-C lamp in the laminar flow cabinet or tissue culture hood was 
switched on to sterilise the shell for 20 minutes and wiped with 1% Vircon solution 
followed by 70% ethanol prior to use. The laminar flow cabinet was allowed to run for 15 
minutes prior to use. All collection work was performed within a sterile tissue culture 
hood. Cell extracts and media were aspirated using single-use serological pipette tips 
(Starlab, Milton Keynes, UK) into RNase-free 2 ml centrifuge tubes. 
2.4.1 Cell culture medium collection 
2.4.1.1 Principles 
The cell culture medium is an excellent source of cell-secreted proteins and hence it was 
used to analyze the environment change caused by cells in a given treatment. 
2.4.1.2 Method 
Reagents and equipment 
Pipette and sterile pipette tips 
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Sterile centrifuge tubes 
Cell medium was aspirated and centrifuged at 249 x g for 10 minutes. The supernatant 
was aspirated and transferred to a sterile centrifuge tube and stored at -80°C. 
2.4.2 TRIzol® collection for total RNA analysis 
2.4.2.1 Principles 
Total adipocyte RNA was obtained by guanidinium thiocyanate–phenol–chloroform 
extraction (Chomczynski and Sacchi, 2006). Guanidinium thiocyanate in the TRIzol® 
solution used is a strong inhibitor of ribonucleases and phenol is utilised for partitioning 
of aqueous supernatant for RNA isolation. 
2.4.2.2 Method 
Reagents and equipment 
Cell cultures in plates 
TRIzol® solution 
Pipette and sterile pipette tips 
Rocking platform 
RNase-free centrifuge tubes 
RNA isolation was performed according to the Trizol Reagent Protocol (Invitrogen, 
Paisley, UK). After the cell medium was aspirated, 500 µl of TRIzol® reagent was added 
in each well and rocked on a rocking platform for 5 minutes to remove cells from the 
bottom of the well. The mixture of TRIzol® and cells was repeatedly pipette up and 
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down to mechanically dislodge cells. The mixture from each well was then collected into 
RNase-free tubes and stored at -80°C to prevent RNA degradation. 
2.4.3 Cell lysate collection 
2.4.3.1 Principles 
Cell lysis is a cell disruption method used to release biological molecules from inside a 
cell. A detergent is used to disrupt cells in this method. Detergent-based lysis is used in 
conjunction with mechanical disruption of cell membranes to achieve a more 
homogenous extract. The sodium dodecyl sulphate detergent used in this study works by 
disrupting the lipid barrier surrounding cells by disrupting lipid-lipid, lipid-protein and 
protein-protein interactions within the cell. Cell lysates were used solely for protein 
assessment by western blotting. In cell signal transduction events, phosphorylation and 
dephosphorylation of proteins define a multitude of cellular processes such as cell 
division, cell proliferation and cell death. Target proteins are phosphorylated by protein 
kinases which work by transferring a phosphate group to a specific protein, usually at 
serine or tyrosine residues. Phosphorylation of a protein tends to change the conformation 
of the protein, altering its ability to interact or bind its complementary ligands. The 
phosphorylated state of these proteins can be diminished if the phosphate group is 
removed by the action of endogenous or exogenous phosphatases. It is therefore highly 
critical that phosphatase inhibitors be used in the lysis to preserve the phosphorylated 
state of the proteins. Endogenous proteases released during the disruption of cells may 
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also degrade proteins. Thus, a broad spectrum protease inhibitor cocktail is used for 
protection of proteins when performing the lysing step. 
2.4.3.2 Reagents and equipment 
Cell lysis buffer consisting of: 
50mM Tris-HCl, pH 6.7 
10% Glycerol 
4% SDS 
2% β-mercaptoethanol 
Protease inhibitor cocktail (1:100) 
Phosphatase inhibitor cocktail (1:100) 
Autoclaved phosphate-buffered saline 
Pipette and sterile pipette tips 
RNase-free centrifuge tubes 
2.4.3.3 Method 
After the cell medium in each well had been aspirated, the cell monolayer was washed 
with three times with 1 ml of autoclaved PBS. Subsequently 50 µl of cell lysis buffer was 
added to each well and pipetted up and down repeatedly to ensure maximum recovery of 
cells. Extracts were aspirated and transferred to RNase-free 2 ml centrifuge tubes.
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2.5 Total RNA isolation 
2.5.1 Principles 
TRIzol® was used to perform guanidinium thiocyanate–phenol–chloroform extraction 
for the isolation of RNA (Chomczynski and Sacchi, 2006). TRIzol® contains 
guanidinium isothiocyanate, which is a strong chaotropic agent that disrupts cells, 
solubilises their components, denatures endogenous RNases and separates rRNA from 
ribosomes. Guanidinium thiocyanate demolishes the three-dimensional structure of 
proteins, converting them to a randomly coiled state, including RNases which as a result 
will not be able to act on RNA. This allows the RNA to come in the free form. The 
solution also contains phenol in an acidic environment which is required for the 
partitioning of RNA into aqueous supernatant for separation (Figure 2.1). Phenol also 
solubilises the proteins. Chloroform used in the technique works to solubilise lipids. A 
low pH is critical for the isolation of RNA as a higher pH will cause DNA to partition 
into the aqueous phase. The other cell proteins and DNA should be confined to the 
interphase and lower organic phase. Total RNA is then recovered by precipitation of the 
aqueous phase with isopropanol and washed of impurities with 75% ethanol. The RNA is 
then dissolved in DEPC-treated water and frozen if not used immediately. 
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Figure 2.1 Isolation of RNA from TRIzol® extracts 
 
 
During phase separation the phenol-chloroform mixture separates the cell homogenate 
into three phases: a clear aqueous phase with the RNA, a white interphase containing 
DNA and a pink organic phase containing cell proteins and lipids. After the precipitation 
step with isopropanol, a white pellet is generated at the bottom of the tube. This is 
subsequently washed with 75% ethanol and solubilised with DEPC-treated water. 
 
54 
 
2.5.3 Method 
Reagents and equipment 
RNase AWAY® 
TRIzol® extracts (Section 2.4.2) 
Chloroform 
75% ethanol 
Isopropanol 
Refrigeration centrifuge 
23-gauge needle and syringe 
Sterile pipette tips and pipette 
Sterile filter pipette tips 
RNase AWAY® was sprayed on gloves and all glass and plastic ware to eliminate RNase 
and DNA contamination from labware. TRIzol® extracts were homogenised by passing 
the cells through a 23 gauge needle four times, ensuring that the needle was changed 
between wells. TRIzol® extracts were thawed in a box of ice and 100 µl of chloroform 
was added into each tube of extract. The tubes were then shaken vigorously for 15 
seconds and left to stand for 10 minutes at room temperature. It was then centrifuged at 
20,800 x g for 15 minutes at 4°C to create three phases: an upper colourless aqueous 
phase containing RNA, a white interphase containing DNA and a lower red phenol phase 
containing protein. The top layer was carefully aspirated into a fresh RNase-free tube, 
ensuring that the interphase DNA was not aspirated as well. 250 µl of isopropanol was 
added to each tube of aqueous extract, vortexed and allowed to stand at room temperature 
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for 10 minutes. The extracts were then centrifuged at 20,800 x g for 15 minutes at 4°C. 
The supernatant was subsequently discarded with care not to dislodge the pellet from the 
base of the tube, which was then vortexed in 100 µl of ethanol. The samples were then 
centrifuged at 15,300 x g for 10 minutes at 4°C. The supernatant was removed and pellets 
were left to air dry for 5 minutes. The pellet was dissolved in 12 µl of ultra-pure water 
(Sigma) and stored at -80°C if not used immediately. 
2.5.4 RNA quantification 
The concentration and the purity of the RNA was determined by measuring the 
absorbance at 260/280 nm using a spectrophotometer (Biophotometer Eppendorf, 
Cambridge, UK) according to the current protocol for RNA extraction (Chomczynski and 
Sacchi, 2006). RNA extracts were thawed and kept on ice throughout the quantitation. 1 
µl of RNA was diluted with 69 µl of ultra-pure water and the absorbance was measured at 
260 nm and 280 nm with ultra-pure water used as a blank. The RNA concentration 
(µg/µl) was automatically calculated by the spectrophotometer. 
The maximum absorbance of nucleic acids is at 260 nm and since RNA has an extinction 
coefficient of 44.19 at that wavelength, the concentration of RNA using the Beer-
Lambert (Beer, 1852) law is as follows: 
Concentration of RNA (µg/ µl) = A260 x 44.19 x Dilution Factor/ 1000 
The ratio between A260 and A280 was used as a measure of RNA purity, where a value of 
2 indicates a pure sample, whereas a value of 1.6 and below is indicative of 
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contamination, which is usually due to protein. RNA extracts were diluted to a 
concentration of 0.1 µg/ µl using the formula as follows: 
Concentration of RNA extract x 1 µl = 0.1 µg/ µl x total volume of dilution 
2.6 Reverse-transcription polymerase chain reaction 
2.6.1 First-strand cDNA synthesis 
2.6.1.1 Principles 
This procedure was used to generate single-stranded DNA strands complementary to the 
mRNA sequences in the total RNA of samples (Krug and Berger, 1987). The iScript first 
strand cDNA Synthesis Kit (Bio-Rad, Hertfordshire, UK) was used and features 
oligo(dT) and random hexamer primers in a unique ratio in the reaction mix. This 
procedure was used to generate first-strand DNA complementary to the mRNA 
sequences in total RNA samples. An RNA-dependent DNA polymerase is derived from 
the retrovirus Molone Murine Leukaemia Virus (MMLV) is used as the reverse 
transcriptase enzyme. The poly(A) tail found at the 3' end of the mRNA acts as a starting 
point for the reverse transcriptase to which a short complementary synthetic 
oligonucleotide (oligo dT primer) is hybridised to form a polyT-polyA hybrid. Random 
hexamers were incorporated to enable priming throughout the length of RNA for uniform 
representation of all RNA sequences, ensures transcription of 5' ends of long mRNAs and 
also allows for reverse transcription of RNAs without poly(A) tails. All four 
deoxynucleotide triphosphates, Mg2+ cofactors and a neutral pH maintained by the kit 
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buffer provide the necessary conditions and resources for cDNA synthesis on the mRNA 
template (Figure 2.2). 
2.6.1.2 Method 
cDNA was synthesised using 0.5 µg of RNA and the iScript first strand cDNA Synthesis 
Kit (Bio-Rad, Hertfordshire, UK). The kit consisted of: 
5X cDNA synthesis kit buffer 
iScript enzyme mixture 
Nuclease-free water 
0.1µg/µl RNA sample 
The procedure was performed using sterile RNase and DNase-free tubes and filter tips. A 
master mix was prepared using 2 µl of reaction mix, 0.5 µl of reverse transcriptase and 
2.5 µl of nuclease-free water per RNA template. 5 µl of master mix and 5 µl of RNA 
template were added to each PCR tube, vortexed and pulse-spun to gather the contents to 
the bottom of the tube. The samples were then placed in a thermal cycler programmed to 
run the following protocol:  
5 min at 25°C 
30 min at 42°C 
5 min at 85°C 
Hold at 4°C 
Once the reaction is complete, 30 µl of ultra-pure water was added to each PCR tube and 
used immediately or stored in -20°C to prevent degradation. 
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Figure 2.2 First-strand cDNA synthesis 
 
cDNA synthesis using an oligo-d(T) primer and reverse transcriptase. 
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2.7 Real-time polymerase chain reaction (RT-qPCR) 
Real-time PCR is the ‘gold-standard’ for quantitating steady-state mRNA levels. It is 
based on the classic principles of PCR and quantifies a targeted DNA molecule during 
the exponential phase based on amplification of DNA. The exponential phase is deemed 
to occur very efficiently early in the reaction process, allowing reliable quantitation of the 
starting DNA. Two types of PCR detection chemistries were used in this study – the 
TaqMan® and SYBR® Green systems. 
2.7.1 Taqman system principles 
The TaqMan® chemistry, also known as ‘fluorogenic 5' nuclease chemistry’, measures 
specific PCR product accumulation using a set of primers and a dual-labeled fluorogenic 
oligonucleotide probe (Holland et al., 1991). The probe is composed of a short 
oligonucleotide sequence of 20 to 30 bases long labelled with two different fluorescent 
dyes. The reporter dye is located at the 5' terminus and a quenching dye (usually 
TAMRA) is located at the 3' terminus. A probe homologous to an internal target 
sequence amplicon anneals to PCR product. When the probe is intact, energy transfer 
occurs between the two fluorophores and emission from the reporter is quenched by the 
quencher by a process called FRET (Förster or fluorescence resonance energy transfer). 
During the extension phase Taq polymerase cleaves the probe, releasing the reporter from 
the oligonucleotide quencher. This ends the activity of FRET and the reporter dye starts 
to emit fluorescence (518nm for FAM) which increases during each cycle proportional to 
the rate of probe cleavage. In the real-time Mx3005P QPCR system, the laser light source 
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excites each well and a CCD camera measures the fluorescence spectrum and intensity 
from each well. A specific requirement for fluorogenic probes is that there should not be 
a G at the 5' end of the probe sequence; a 'G' adjacent to the reporter dye is able to quench 
reporter fluorescence even after cleavage. The MxPro qPCR software measures the 
fluorescent activity of reporter dyes and a software algorithm is used to calculate and 
normalise the increase of reporter emission intensity over the extension phase (dRn) to a 
passive reference dye (ROX). Normalization is essential to correct for differences in 
reaction mix volumes between wells. The amplification plot is examined at a point early 
in the log phase of product accumulation. This is done by assigning a fluorescence 
threshold and a cycle threshold (Ct) value is determined when the fluorescence from a 
sample crosses the threshold. 
2.7.2 SYBR Green principles 
SYBR Green I is an asymmetrical cyanine dye used as a nucleic acid stain in molecular 
biology (Zipper et al., 2004). SYBR Green I stains DNA and RNA, although it binds 
preferentially to double-stranded DNA and stains single-strand DNA and RNA with 
lower performance. The resulting DNA-dye-complex absorbs blue light (λmax = 488 nm) 
and emits green light (λmax = 522 nm). SYBR®-Green based detection uses the SYBR 
Green I dye which functions to detect PCR product as it accumulates during PCR cycles. 
When the dye is added to a sample, it immediately intercalates between the base pairs of 
all double-stranded DNA present in the sample (Ponchel et al., 2003). During the PCR 
reaction, AmpliTaq Gold® DNA Polymerase amplifies the target sequence, creating new 
double-stranded DNA or amplicons. The SYBR Green I dye then binds to each new 
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amplicon as the reaction progresses and more amplicons are generated, resulting in an 
increase in fluorescence intensity proportionate to the amount of PCR product produced. 
The MxPro qPCR software measures the fluorescent activity of the dye and a software 
algorithm is used to calculate and normalise the increase of fluorescent emission intensity 
over the extension phase (dRn) to a passive reference dye (ROX). Again, normalization is 
essential to correct for differences in reaction mix volumes between wells. The 
amplification plot is examined at a point early in the log phase of product accumulation. 
This is done by assigning a fluorescence threshold and a cycle threshold (Ct) value is 
determined when the fluorescence from a sample crosses the threshold. The SYBR Green 
chemistry follows a slightly different protocol from the TaqMan chemistry. Real time 
SYBR Green PCR amplification cycling steps features a 95°C denaturation step for 10 
minutes followed by 40 cycles consisting of a 95°C denaturation step for 15 seconds and 
an annealing-cum-extension step 60°C for 1 minute) and an additional dissociation cycle 
(95°C for 1 min, 55°C for 30 s and 95°C for 30 s). The dissociation step shows the 
number of PCR products and is used to gauge the specificity of the amplification. This is 
important as the SYBR Green dye is capable of binding to any double-stranded amplicon, 
by binding with non-specific double-stranded DNA sequences and generating false-
positive signals. False-positive signals can be minimised or prevented by using a master 
mix and primer combination that only generates a single gene-specific amplicon without 
producing secondary non-specific products.  
The figure shows a screenshot of an amplification plot with default settings as viewed 
from the MxPro software. The baseline is adjusted ideally above the background 
fluorescence as exemplified here, within the exponential phase of the PCR.
Figure 
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2.3 Amplification plot
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2.7.3 Preparation of 96 well plates for real-time PCR 
2.7.3.1 Taqman assay reagents 
qPCR core kit consisting of: 
10 x reaction buffer 
50mM magnesium chloride 
5mM dNTP mix 
5 U/ ml Hot Goldstar enzyme 
Forward and reverse primers 
Taqman probe 
Ultra-pure water 
2.7.3.2 Taqman assay method 
Working solutions of primers and probes were reconstituted to produce a 100 µM stock. 
Each 12.5 µl reaction contained the following: 
Component Amount (ul) per well 
10x buffer 1.25 
MgCl2 1.25 
dNTP 0.5 
Forward Primer 0.038 
Reverse Primer 0.038 
Probe 0.063 
Hot Goldstar Enzyme 0.0625 
Ultra-pure water 8.3 
Total master mix volume per well 11.5 
64 
 
 
A master mix sans cDNA was made up with a 2-well excess to allow for pipetting errors. 
1µl of the synthesised cDNA (equivalent to 10 ng of cDNA) was loaded into each well of 
a 96 well plate for RNA detection. Real-time amplification was performed in a final 
volume of 12.5 µl made up of cDNA, optimised concentrations of primers, Taqman probe 
(FAM-TAMRA) and a master mix made from a qPCR core kit (Eurogentech, Seraing, 
Belgium). Real time PCR amplification was performed in duplicates in a Strategene 
Mx3005P instrument. A non-template control well was added to each plate. The plate 
was spun at 500 x g for 1 minute to gather the contents to the bottom of the wells. The 
plate was inserted into the heat block of the Mx3005P qPCR instrument with an optical 
pad placed on top and aligned with the well positions. PCR cycling conditions were as 
follows: 95°C denaturation step for 10 minutes followed by 40 cycles (95°C denaturation 
step for 15 seconds and annealing-cum-extension step at 60°C for 1 minute). Data was 
collected automatically in real-time by the MxPro software and analysed at the end of the 
run. 
2.7.3.3 SYBR Green assay reagents 
qPCR core kit consisting of: 
10 x reaction buffer 
50mM magnesium chloride 
5mM dNTP mix 
5 U/ ml Hot Goldstar enzyme 
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Forward and reverse primers 
Ultra-pure water 
2.7.3.4 SYBR Green assay method 
Working solutions of primers were reconstituted to produce a 100 µM stock. Each 12.5 µl 
reaction contained the following: 
Component Amount (ul) per well 
10x buffer 1.25 
MgCl2 0.875 
dNTP 0.5 
Forward Primer 0.038 
Reverse Primer 0.038 
SYBR Green dye 0.375 
Hot Goldstar Enzyme 0.062 
Ultra-pure water 8.362 
Total master mix volume per well 11.5 
 
Real-time amplification of VDR and GLUT-4 RNA was performed by preparing a master 
mix sans cDNA was made up with a 2-well excess to allow for pipetting errors. 1µl of the 
synthesised cDNA (equivalent to 10 ng of cDNA) was loaded into each well of a 96 well 
plate for RNA detection. Real-time amplification was performed in a final volume of 
12.5 µl made up of cDNA and master mix. Real time PCR amplification was performed 
in duplicates in a Strategene Mx3005P instrument. A non-template control well was 
added to each plate. The plate was spun at 500 x g for 1 minute to gather the contents to 
the bottom of the wells. The plate was inserted into the heat block of the Mx3005P qPCR 
instrument with an optical pad placed on top and aligned with the well positions. 
66 
 
Real time PCR amplification was performed in duplicates and PCR cycling conditions 
were as follows: 95°C denaturation step for 10 minutes followed by 40 cycles consisting 
of a 95°C denaturation step for 15 seconds and an annealing-cum-extension step 60°C for 
1 minute) and 1 dissociation cycle (95°C for 1 min, 55°C for 30 s and 95°C for 30 s). The 
dissociation step shows the number of PCR products and is used to gauge the specificity 
of the amplification. This is important as the SYBR Green dye is capable of binding to 
any double-stranded amplicon, which lowers its specificity. 
2.7.4 Analysis of real-time PCR data 
Amplification plots were converted to log scale using the MxPro software and the 
threshold was manually adjusted following these following parameters:  
1. Linear phase of amplification 
The threshold should be placed within the exponential phase of amplification 
across all the amplification plots. The linear region is depicted in the log plots and 
should not be placed too close to the plateau phase or the initial linear phase of 
amplification where it is too low and extends into the background fluorescence. 
2. Precision maximization 
The threshold should be set at a point where the most precise points of 
amplification can be measured. The precision of replicates tend to increase as the 
reaction progresses along the exponential phase. This is usually achieved by 
adjusting the threshold within the exponential range above the background noise. 
3. Sensitivity maximization 
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The threshold should be set upon the point where it best reflects the orders of 
magnitudes across the assay. 
The Ct values for each gene was exported to Microsoft Excel and gene expression was 
analysed by relative quantification by using the 2-∆∆CT method (Livak and Schmittgen, 
2001). β-actin was used as a reference gene. All samples were normalised to the β-actin 
Ct values and the results expressed as fold changes of Ct value relative to controls. 
2.7.5 Primer and probe sequences 
The sequences of primers and probes for human β-actin, ZAG, Adiponectin, IL-1β, IL-6, 
MCP-1 and VDR are described in Table 2.1. The primers for human β-actin, ZAG, 
adiponectin and IL-6 are as described in Bao et al. (2005). The primer for MCP-1 is as 
described in Wang et al., (2005). IL-1β and VDR primers were designed using Primer 
Premier 5 software (Biosoft International, California, USA) and synthesised 
commercially (Sigma, Poole, Dorset, UK). 
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Table 2.6 Primer and probe sequences of human target genes 
Transcript  Primer sequence 
Human β-actin  
 Forward 5′-GGATGCAGAAGGAGATCACTG-3′ 
 Reverse 5′-CGATCCACACGGAGTACTTG-3′ 
 Probe 5′-FAM-CCCTGGCACCCAGCACAATG-TAMRA 
Human ZAG  
 Forward 5′-ACGACAGTAACGGGTCTCACGTA-3′ 
 Reverse 5′-TCCTTTCCATCATAGTAATATTTCCAGAA-3′ 
 Probe 
5′-FAM-CAGGGAAGGTTTGGTTGTGAGATCGAGAATAAC-
TAMRA 
Human Adiponectin  
 Forward 5′-CCCAAAGAGGAGAGAGGAAGCT-3′ 
 Reverse 5′-GCCAGAGCAATGAGATGCAA-3′ 
 Probe 5′-FAM-TTCCCAGATGCCCCAGCAAGTGTAAC-TAMRA 
Human IL-6  
 Forward 5′-GGTACATCCTCGACGGCATCT-3′ 
 Reverse 5′-GTGCCTCTTTGCTGCTTTCAC-3′ 
 Probe 
5′-FAM-TGTTACTCTTGTTACATGTCTCCTTTCTCAGGGCT-
TAMRA 
Human MCP-1  
 Forward 5′-CATAGCAGCCACCTTCATTCC-3′ 
 Reverse 5′-TCTGCACTGAGATCTTCCTATTGG-3′ 
 Probe 5′-FAM-CAGCCAGATGCAATCAATGCCCC-TAMRA 
Human IL-1β  
 Forward 5′-TGGCCCTAAACAGATGAAGTGC-3′ 
 Reverse 5′-GTAGTGGTGGTCGGAGATTCG-3′ 
 Probe 5′-FAM-ACCTGGACCTCTGCCCTCTGGATGG-TAMRA 
Human VDR (SYBR green)  
 Forward 5′-AAGCGGAAGGAGGAGGAG-3′ 
 Reverse 5′ -TGGCAGAAGTCGGAGTAGG-3′ 
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2.8 Enzyme-linked immunosorbent assay (ELISA) 
2.8.1 ELISA principles 
Enzyme-linked immunosorbent assay (ELISA) is a biochemical technique used to detect 
the release of proteins by human primary adipocytes (Engvall and Perlmann, 1971). A 
molecule of protein is detected by antibodies that have been made against it. The ELISA 
kits used in this study are suited for the measurement of natural or recombinant target 
proteins produced by human cells and are designed for the analysis of cell culture 
supernates. The technique involves the capture of target proteins from cell culture 
supernates to the wells of a microtiter plate coated with a monoclonal antibody against 
the target protein. The coated wells are first blocked of non-specific binding sites before 
incubating with cell culture supernates. The wells are then washed with a washing buffer 
and a secondary biotinylated detection antibody (anti-human target protein antibody) is 
added and incubated to bind with the antigens. Unbound antibodies are washed away and 
a streptavidin-horseradish peroxidise conjugate is added, which binds to the biotin on the 
detection antibody. The unbound conjugates are washed away and a substrate solution 
consisting of equal volumes of hydrogen peroxide and tetramethylbenzidine (TMB) is 
added and the wells are incubated at room temperature. The horseradish peroxidise 
(HRP) enzyme catalyzes the electron transfer from TMB to the peroxide, oxidising TMB 
and a blue colour develops. Colour development is stopped by adding an acid, turning the 
solution colours to yellow. The absorbance is subsequently measured at 450nm with a 
wavelength correction set to 570nm. Adiponectin, IL-1β, IL-6 and MCP-1 in cell culture 
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medium were measured using this method in DuoSet ELISA Development kits purchased 
from R&D (Abingdon, UK). 
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Figure 2.4 Schematic diagram of ELISA 
 
 
Diagramatic representation of an enzyme-linked immunosorbent assay. 
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Human ZAG was measured in cell culture medium using an ELISA kit purchased from 
BioVendor (Heidelberg, Germany). The ELISA technique used was slightly different 
from the other kits used in the study. Wells pre-coated with polyclonal anti-human ZAG 
were incubated with samples and standards and the wells were subsequently washed of 
unbound material. Instead of using a biotinylated detection antibody, polyclonal anti-
human ZAG antibodies conjugated with HRP were added to the wells, incubated and 
washed. The bound HRP conjugates are then allowed to react with the TMB substrate 
solution to produce a blue colour and the reaction was subsequently stopped with acid 
solution. The resulting yellow product is measured at 450nm with a reference wavelength 
of 630nm. Unknown concentrations were determined using a standard curve constructed 
by plotting absorbance values against known concentrations of standards in the 
Microplate Manager version 5.2 software provided by Bio-Rad. 
2.8.2 Method 
2.8.2.1 MCP-1, IL-6, Adiponectin, IL-1β ELISA using R&D Systems development kits 
Reagents and equipment 
Phosphate-buffered saline (PBS) 
Reagent diluents (1% BSA in PBS) 
Capture antibody (Diluted to working concentration with PBS) 
Detection antibody (diluted to working concentration with reagent diluent) 
Recombinant human standard (Diluted in various 2-fold serial dilutions for 7 point 
standard curve, excluding blank) 
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Streptavidin-HRP 
Wash buffer (0.05% Tween-20 in PBS) 
Substrate solution mixture (1:1 in volume of hydrogen peroxide and 
tetramethylbenzidine) 
Stop solution (2M Sulphuric acid) 
96-well MaxiSorp® flat-bottom microplate 
BenchmarkTM Plus Microplate Spectrophotometer 
Multi-channel pipette 
The capture antibody is diluted with PBS to produce a working solution (Table 2.2). A 
96-well MaxiSorp® flat-bottom microplate was coated with 100 µl of antibody working 
solution and sealed to incubate overnight. The wells were washed with wash buffer the 
following day using a multi-channel pipette and plates were blocked with 300 µl of 
reagent diluent for an hour. The wells were washed with wash buffer again and 100 µl of 
sample and diluted standards were added to each well in duplicates. The wells were 
covered with an adhesive strip and left to incubate at room temperature for 2 hours. The 
wells were washed with wash buffer again and 100 µl of detection antibody working 
solution (Table 2.2) was added to each well. The wells were incubated for 2 hours and 
washed again with wash buffer. 100 µl of Streptavidin-HRP was then added to each well 
and incubated for 20 minutes at room temperature, taking care not to expose the plate to 
direct light. The wells were washed with wash buffer. 100 µl of substrate solution was 
then added to each well and incubated for another 20 minutes or till the colour was 
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developed satisfactorily. When a satisfactory development end-point had been reached, 
50 µl of Stop Solution was added to each well and the wells were gently tapped to ensure 
thorough mixing. The optical density was determined by reading the plate in the 
microplate spectrophotometer at 450nm with a reference wavelength of 570nm to correct 
for optical imperfections on the plate. The concentrations of proteins were determined 
using the standard curve generated, ensuring any dilution factors used were entered into 
the calculation. Samples treated with macrophage-conditioned medium were diluted 1 in 
6 for IL-6 determination and 1 in 10 for MCP-1 determination based on pilot studies. 
Adiponectin and IL-1β was analysed neat. Data was collected and plotted using the 
Microplate Manager v5.2 software. A standard curve was generated and points were 
plotted to achieve a best-fit correlation coefficient of >0.96. The ideal correlation 
coefficient is 1, although an R-value of more than >0.96 was accepted for generated 
standard curves. The equation of the best-fit curve or line was used to calculate the 
concentration of proteins. 
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Table 2.7 Antibody and standard concentrations used for ELISA 
Protein measured Capture antibody 
working solution 
concentration 
Detection antibody 
working solution 
concentration 
Concentration of 
S1 (first point) 
Human 
adiponectin 
2.0 µg/ ml 2.0 µg/ ml 4000 pg/ ml 
Human IL-1β 4.0 µg/ ml 200 ng/ ml 250 pg/ ml 
Human IL-6 2.0 µg/ ml 50 ng/ ml 600 pg/ ml 
Human MCP-1 1.0 µg/ ml 100 ng/ ml 1000 pg/ ml 
 
2.8.2.2 ZAG ELISA using BioVendor kits 
Reagents and equipment 
Antibody coated microtitre strips 
Conjugate solution 
Substrate solution 
Stop solution 
Dilution buffer concentrate 2x (diluted in double distilled water to prepare 1x 
working solution) 
Recombinant human ZAG master standard 
Streptavidin-HRP 
Wash solution concentrate 10x (diluted ten-fold in distilled water to prepare 1x 
working solution) 
Double distilled water 
Sterile centrifuge tubes 
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Orbital microplate shaker 
BenchmarkTM Plus Microplate Spectrophotometer 
Multi-channel pipette 
100 µl of diluted standard and dilution buffer (as blank) and samples were pipette into 
assigned wells. The plate was incubated at room temperature for 1 hour on the orbital 
microplate shaker. Wells were washed thrice with wash solution using a multi-channel 
pipette. 100 µl of conjugate solution was added into each well and the plate was 
incubated for 1 hour at room temperature on the orbital microplate shaker. The wells 
were washed thrice again and tapped strongly against a paper towel to remove excess 
wash solution. 100 µl of substrate solution was added into each well, ensuring the plate 
was not exposed to direct sunlight. The plate was incubated for 10 minutes and checked 
for its colour. More time was given for it to develop if the development was 
unsatisfactory (possibly due to colder room temperatures). The colour development was 
stopped by adding 100 µl of stop solution. The OD for each well was read at 450nm with 
a reference wavelength of 630nm to correct for plate imperfections. Concentrations of 
proteins were determined from a standard curve generated using the Microplate Manager 
v5.2 software. A standard curve was generated and points were plotted to achieve a best-
fit correlation coefficient of >0.96. The ideal correlation coefficient is 1, although an R-
value of more than >0.96 was accepted for generated standard curves. The equation of the 
best-fit curve or line was used to calculate the concentration of proteins. 
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2.9 Protein detection using western blotting 
2.9.1 Western blotting principles 
The western blotting technique (Towbin et al., 1979) was used to detect protein 
expression within human primary adipocytes. Cell lystaes were collected with lysis buffer 
added with protease and phosphatase inhibitor cocktails. A priori, a protease inhibitor 
cocktail serves to prevent resident and exogenous proteases from breaking down proteins 
in the lysate. Similarly, a phosphatase-inhibitor cocktail was added to the lysis buffer to 
prevent phosphatases from breaking down phosphorylated proteins (i.e. phosphorylated 
p38 MAPK signalling proteins). Cell lysates were first quantified by the bicinchoninic 
acid (BCA) method. The concentration value of proteins measured by the BCA method 
was obtained and used to calculate the amount of lysate that should be added to each 
well. Lysates were then stained with a loading buffer containing SDS and β-
Mercaptoethanol. SDS gives the protein a negative charge and β-Mercaptoethanol 
prevented the reformation of disulphide bonds. Diluted lysates were then added to each 
well of a sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel 
(Shapiro et al., 1967). After the proteins were sufficiently separated electrophoretically, 
they were transferred from the gel to a nitrocellulose membrane and probed using 
antibodies binding-specifically to a protein of interest. Western blotting relies on the 
ability of the primary antibody to detect the protein of interest from the total amount of 
protein in each individual lysate. To achieve this, the nitrocellulose membrane is blocked 
with a solution of bovine serum albumin or skimmed milk before the addition of a 
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primary antibody. A secondary antibody-HRP conjugate specific to the primary antibody 
used is then added to bind to the nitrocellulose membrane. The HRP conjugated to the 
secondary antibody converts a luminol substrate to a chemiluminescent substance and the 
signal intensity is then detected with the CCD camera of the ChemiDoc™ XRS+ 
molecular imager. Western blotting was used in this study as a semi-quantitative method 
to assess the relative expression of proteins between treatment groups. 
2.9.2 Protein quantification by the Bicinchoninic acid method 
2.9.2.1 Reagents and equipment 
Bicinchoninic acid solution 
Copper (II) sulphate solution 
1 mg/ ml bovine serum albumin protein standard 
Double distilled water 
96-well microplate 
Orbital microplate shaker 
BenchmarkTM Plus Microplate Spectrophotometer 
Total cellular protein was measured using the bicinchoninic acid method (Smith et al., 
1985). Total cellular protein samples were prepared by lysing cells in lysis buffer (50mM 
Tris-HCl, pH 6.7, 10% Glycerol, 4% SDS, 2% 2-mercaptoethanol) with freshly added 
protease inhibitor cocktail and phosphatase inhibitor cocktail (both from Sigma, Poole, 
Dorset, UK). A standard curve was plotted by serial diluting a bovine serum albumin 
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(BSA) standard with double distilled water with final concentrations of 0.2, 0.4, 0.6, 0.8, 
1.0 mg/ ml. Cell lysates were 0.5x diluted in wells by pipetting 5 µl of double distilled 
water to 5 µl of cell lysate. A 50:1 bicinchoninic acid to copper sulphate solution was 
prepared and 200 µl of this mixture was added to each well of a diluted sample or 
standard. The plates were shaken on an oscillator for 1 minute and then incubated in an 
hybridization oven for 30 minutes. The plate was then read in a spectrophotometer at 
570nm. The concentrations of proteins were determined using the standard curve 
generated (Figure 2.5) and multiplying it by a dilution factor of 2. Data was collected and 
plotted using the Microplate Manager v5.2 software. A standard curve was generated and 
points were plotted to achieve a best-fit correlation coefficient of >0.99. The ideal 
correlation coefficient is 1, although an R-value of more than >0.99 was accepted for 
generated standard curves. The equation of the best-fit curve or line was used to calculate 
the concentration of proteins of lysates. 
  
80 
 
Figure 2.5 Standard curve generation for Bicinchoninic acid method 
 
 
 
A sample standard curve was generated using a diluted BSA standard. Standard curve 
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2.9.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
2.9.4.1 Reagents and equipment 
PageRuler protein marker (Fermentas) 
Loading buffer 
1 ml 0.5M Tris-HCL, pH 6.8 
1.6 ml 10% SDS 
0.4 ml β-Mercaptoethanol 
1 ml Glycerol 
0.01g Bromophenol blue 
3 x Gel Buffer 
18.16g Trizma base 
10 ml 5M hydrochloric acid 
0.75 ml 20% SDS 
Double-distilled water (made up to 50 ml total volume) 
Separating gel 
2 ml 48% acrylamide/ 1.5% bisacrylamide mix 
3.64 ml double distilled water 
3.3 ml 3 x gel buffer 
1 ml glycerol 
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50 µl ammonium persulphate 
6 µl tetramethylethylenediamine (TEMED) 
Stacking gel 
0.4 ml 48% acrylamide/ 1.5% bisacrylamide mix 
3.36 ml double distilled water 
1.2 ml 3 x gel buffer 
40 µl ammonium persulphate 
4 µl TEMED 
Cathode buffer 
12.11g Trizma base (100 mM) 
17.92g Tricine (100 mM) 
5 ml 20% SDS (0.1%) 
Double distilled water (made up to 1000 ml total volume) 
Anode buffer 
24.22 Trizma base 
6 ml 1M hydrochloric acid 
Double distilled water (made up to 2000 ml total volume) 
Gel electrophoresis equipment 
Bio-Rad Mini-PROTEANTM Tetra System 
2.0 mm notched glass plates 
2.0 mm plain glass plates 
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1.0mm comb, 10 or 15 wells 
Casting base with silicone seals 
Components were mixed together in a sterile 2 ml centrifuge tube to make the loading 
buffer. Any unused loading buffer was stored at -20°C for not more than 3 months. All 
gel electrophoresis components were cleaned with ethanol, dried and assembled 
according to the manufacturer’s instructions. The glass plates were assembled and locked 
into position onto the casting base. Distilled water was first poured between the glass 
plates to ensure there were no leaks. The water was removed using filter paper. The 
separating gel was prepared and pipetted quickly and carefully between the glass plates, 
preventing the formation of bubbles and leaving a third of the space for the stacking gel. 
0.1% SDS was added to the top of the gel to prevent the gel from drying out while it sets. 
Once the gel had set, the SDS was tipped out and the excess was removed with filter 
paper. The stacking gel was prepared and pipetted to fill the remaining third of space 
between the glass plates. The comb was promptly inserted and the stacking gel was 
allowed to set for 30 minutes. Samples were diluted 10x with loading buffer and placed 
in a heating block at 80°C to denature proteins for 5 minutes. The combs were removed 
and gels were taken off the casting base and assembled into the gel tank. The tank was 
then filled with cathode buffer between the glass plates to the brim to completely 
submerge the gel. 40µg of each sample was added to each lane and a PageRuler™ protein 
marker was added to occupy one lane. Anode buffer was added to the exterior 
compartment to the designated mark. The electrodes were connected and run at 45V for 
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an hour for distinct separation of cells and then 85V till the bromophenol blue dye runs 
out of the gel.  
2.9.5 Electroblotting 
2.9.5.1 Reagents and equipment 
Transfer buffer 
3.03g Tris-base (25mM) 
14.4g Glycine (192mM) 
200 ml methanol (20%) 
Double distilled water (made up to 1000ml volume) 
Electroblotting equipment 
Fibre pads 
Thick blotting paper 
Hybond ECL nitrocellulose membrane 
Compression Cassettes 
Bio-Rad Mini-PROTEANTM Tetra cell running tank 
Internal electroblotting adapter 
0.1% TTBS 
0.1% Tween-20 
20 mM Tris-base 
500 mM sodium chloride 
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Double distilled water 
Filter paper and nitrocellulose membrane was soaked in distilled water and then transfer 
buffer. The cassettes were opened and the sandwich was assembled by laying 
components in the following order from the bottom: foam pad – blotting paper – transfer 
membrane – gel – blotting paper – foam pad. Care was taken to ensure there were no 
bubbles between the transfer membrane and gel. The cassettes were closed and locked 
and inserted into the adapter. The setup was run at 100V for 70 minutes. The membrane 
was washed in a 0.1% TTBS and stained in Ponceau S solution. The membrane was 
briefly rinsed and the gel was scanned using an HP precision imaging scanner. 
2.9.6 Immunological detection of proteins 
2.9.6.1 Reagents and equipment 
5% BSA in 0.1% TTBS (Blocking solution) 
0.1% TTBS 
Primary antibodies 
Secondary antibodies 
Luminol enhancer and stable peroxide buffer (Supersignal® West Pico ECL kit) 
The membrane was washed of Ponceau S stain and blocked with 5% BSA for 30 minutes 
at room temperature. Primary antibodies were added to the BSA incubation solution to a 
1:1000, 1:2000 or 1:20,000 ratio depending on the instructions furnished on the insert. 
The membrane was incubated on a shaking platform overnight at 4°C. Monoclonal 
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antibodies were preferred over polyclonal antibodies to reduce the background associated 
with non-specific binding. The membranes were washed were 10 minutes 4 times with 
fresh 0.1% TTBS each time on a shaking platform. The membrane was submerged in 5% 
BSA and secondary antibodies conjugated with HRP were added to a ratio according to 
the insert provided and incubated for 1 hour at room temperature on a shaking platform. 
The membrane was subsequently washed for 4 times again in 0.1% TTBS for 10 minutes 
each time. To reduce the signal induced by Tween-20, the membrane was rinsed in TBS 
before moving on to the enhanced chemiluminescence (ECL) step. The luminol enhancer 
and stable hydroxide peroxide solution was added in a 1:1 ratio, incubated for 1 minute 
and the excess solution mixture was dripped off. The membrane was enclosed in clear 
plastic folder, carefully ensuring bubbles were not introduced into the folder. The 
development was scanned in the ChemiDoc™ XRS+ System and the cumulative signals 
were read over a period of 40 minutes. The antibody concentrations and conditions 
reflected in Table 2.8 were used for each probe. 
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Table 2.8 Antibody dilutions and conditions used for western blots 
Antibodies Provider Dilutions Incubating solution 
GAPDH 
(Housekeeping 
protein) 
Abcam 1:2000 5% BSA in TBS and 
0.1% Tween-20 
Human Іκβα New England 
Biolabs  
1:1000 5% BSA in TBS and 
0.1% Tween-20 
Insulin-receptor 1β Sigma 1:1000 5% skimmed milk in 
TBS and 0.1% 
Tween-20 
Phosphororylated 
NF-κB p65 
Sigma 1:1000 5% BSA in TBS and 
0.1% Tween-20 
Phosphorylated p38 
MAPK 
New England 
Biolabs 
1:1000 5% BSA in TBS and 
0.1% Tween-20 
 
2.9.7 Relative quantitation of proteins 
The optical density of band images produced by the molecular imager was determined by 
densitometry using the Image Lab software provided along with the Chemidoc XRS+ 
molecular imager. The volume values were exported to Excel and the relative densities 
were measured against the optical density for GAPDH as a housekeeping reference 
protein. 
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2.10  Cytotoxicity tests 
2.10.1 LDH Assay 
2.10.1.1 Principles 
The cell-free culture medium is incubated with substrate mixture using a colourimetric 
cytotoxicity detection kit (Roche Diagnostics GmbH, Mannheim, Germany). LDH 
activity is determined using a coupled enzymatic reaction where the tetrazolium sale is 
reduced to formazan. The water-soluble formazan dye is measured at 492nm with a 
reference wavelength of 620nm. The formazan dye intensity increases with the amount of 
LDH enzyme activity associated with an increase in the number of dead cells. 
2.10.1.2 Method 
Reagents and equipment 
Catalyst (Diaphorase/NAD + mixture) 
Dye solution (INT and sodium lactate) 
BenchmarkTM Plus Microplate Spectrophotometer 
96-well microplate 
Orbital microplate shaker 
The release of lactate dehydrogenase (LDH) into the cell culture medium after treatment 
with 25% THP-1 MC medium or 25% RPMI, with or without calcitriol, was performed 
using a colourimetric cytotoxicity detection kit (Roche Diagnostics GmbH, Mannheim, 
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Germany). LDH concentration was measured with a spectrophotometer at 492nm with a 
reference wavelength of 620 nm at room temperature. 
2.11 Transmigration assay 
2.11.1 Principles 
The Chemicon QCMTM 5µm 96-well Migration Assay is used for this technique based on 
the Boyden chamber (Boyden, 1962). Migratory cells on the bottom of the insert 
membrane dissociate from the membrane when incubated with Cell Detachment Buffer. 
These cells are subsequently lysed and detected by the MTT assay method. The MTT 
assay is a colorimetric assay that measures the reduction of yellow 3-(4,5-dimethythiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) by mitochondrial succinate 
dehydrogenase. The MTT solution enters the cell mitochondria where it is reduced to a 
dark purple formazan product. The cells are then solubilised with a lysis buffer with an 
organic solvent and the released solubilised formazan product is measured 
spectrophotometrically. This assay works with the principle that reduction of MTT was 
only occur in metabolically active cells with mitochondrial activity and the intensity of 
formazan product can only be measured with live cells. Most migration assays utilise an 
8µm pore size, as this is appropriate for most cell types, e.g. epithelial and fibroblast 
cells. However the Chemicon QCMTM 5µm 96-well Migration Assay features a 5µm pore 
size, which was chosen for its suitability for studying monocyte/macrophage migration. 
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2.11.2 Method 
Reagents and equipment 
QCM™ Chemotaxis 5µm 96-Well Cell Migration Assay kit consisting of a feeder 
tray and cell suspension chamber inserts  
RPMI-1640 medium 
Cell culture medium samples 
THP-1 cell monocyte suspension 
5 mg/ ml MTT solution 
Lysis buffer consisting of: 
20% SDS 
50% dimethylformamide 
2% glacial acetic acid to adjust solution to pH 4.7  
Orbital microplate shaker 
BenchmarkTM Plus Microplate Spectrophotometer 
Pipette and sterile pipette tips 
Human THP-1 monocytes were prepared at a density of 2 x 106 cells/ml in 11 ml of 
RPMI 1640 medium. THP-1 cells were counted to obtain a total of 22 x 106 cells for a 
96-well analysis. Cells were centrifuged for 5 minutes and washed once with RPMI1640 
medium. Cells were then resuspended to its former density in RPMI-1640 medium. 150 
µl of human primary adipocyte culture medium from the cell culture treatments were 
added into the wells of the feeder tray of a QCM™ Chemotaxis 5µm 96-Well Cell 
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Migration Assay kit (Fisher Scientific, Loughborough, UK). 100 µl of THP-1 monocyte 
suspension was added into the cell suspension chamber. The plate was covered and 
incubated for 4 hours at 37°C in a humidified atmosphere of 5% CO2 and 95% air. A cell 
density curve plate containing a series of human THP-1 cell concentrations was also 
prepared concurrent to the test plate. 25µl of MTT solution (5 mg/ml in PBS, 0.22 µm 
filtered) was added to the wells of the feeder tray and standard curve plate and incubated 
for 4 hours. 50 ul MTT lysis buffer was added to each well and the wells were incubated 
overnight. The wells were read spectrophotometrically at 570 nm in a plate reader. Cell 
numbers from each OD reading were calculated based on the cell density standard curve.  
2.12   Statistical analysis 
All results are presented as means ± standard deviation (SD) and group size varied 
between experiments. Differences between two groups were analysed by Student’s 
unpaired t-test, while differences among more than two groups were assessed by one-way 
ANOVA coupled with Bonferroni’s t-test. Differences were considered as statistically 
significant when P < 0.05. All P-values were two-sided. Statistical tests were performed 
using Graphpad Prism version 5.03 (Graphpad software Inc., California, USA) and SPSS 
(PASW), release version 19.0 (IBM SPSS, Feltham, UK) 
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Chapter 3  
Macrophage-induced inflammatory response in 
human primary adipocytes
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3.1 Introduction 
Several researchers have found that the increased macrophage infiltration in adipose 
tissue in obesity provides a central link between inflammation and metabolic disease 
(Weisberg et al., 2003; Cancello et al., 2005, Curat et al., 2006). It is believed that 
macrophage infiltration of adipose tissue contributes to low-grade inflammation, causing 
a chronic elevation of inflammatory cytokines in the systemic circulation which is 
commonly associated with metabolic disease. 
Macrophage-secreted factors have been shown to exert profound effects on the behaviour 
of adipose tissue. Some effects include the decrease of adiponectin production in 
preadipocytes (Constant et al., 2006), stimulating leptin expression in mice adipose tissue 
(Hirasaka et al., 2007) and the expression of many inflammation-related genes in human 
adipocytes (O’Hara et al., 2009). Recent studies by our group showed the decrease in 
production of zinc-α2-glycoprotein (ZAG) by human primary adipocytes incubated with 
macrophage-conditioned medium (Gao et al., 2010). Gao and Bing (2011) also showed 
an upregulation of matrix metalloproteinases MMP1 and MMP3 which are involved in 
adipose tissue remodelling and inflammatory responses in obesity. It was postulated in 
Fain (2006) that many of these effects caused by inflammatory mediators produced by 
macrophages and cells of the SVF. 
There is, however, a lack of studies that seek to define the mechanisms of inflammation 
resulting from specifically human primary adipocyte and macrophage crosstalk. This is 
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particularly important as current evidence suggests that this crosstalk can modulate 
adipocyte responses (Suganami et al., 2005). The evidence also suggests that adipokines 
produced by adipocytes present the initial errant signal that could possibly spark off the 
‘inflammatory chain reaction’. The vast expanse of the adipose organ throughout the 
human body would also mean that any change, even if small in magnitude, is capable to 
producing important paracrine and endocrine outcomes - especially in the long-term. 
In vitro studies on human primary adipocytes, therefore, are essential to find the exact 
effect by which macrophages increase inflammation in fat tissue. Such a model allows 
better resolution of a cause-effect relationship as one is able to eliminate more 
confounding variables compared to an in vivo model. This study features the novel use of 
human adipocytes and monocytes with the purpose of enhancing the clinical relevancy of 
the findings. The use of a 25% THP-1 monocyte conditioned medium also creates a 
physiological model for macrophage infiltration within adipose tissue. Macrophage-
conditioned medium is obtained from PMA-differentiated THP-1 monocytic cells 
maintained in RPMI-1640 medium for 24 hours to collect cytokines and chemokines 
secreted by THP-1 macrophages. This may include TNF-α, IL-6, MCP-1, RANTES, IL-8 
(Gao et al., 2010) and IL-1β (Xu et al., 2003; Wen et al., 2011). The harvested THP-1 
conditioned medium, diluted to 25% with cell maintenance medium, is used for the 
studies of crosstalk between macrophages and human primary adipocytes. To study the 
specific effect of TNF-α, a proinflammatory cytokine produced by macrophages, cells are 
incubated with TNF-α to identify its specific effect on human primary adipocytes. 
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3.2 Changes in proinflammatory mediator production by 
human primary adipocytes stimulated by macrophage-
secreted factors 
3.2.1 Gene expression and secretion of MCP-1, IL-6 and IL-1β by adipocytes 
stimulated with macrophage-conditioned medium or TNF-α 
Human primary adipocytes (at day 13 post-differentiation) were incubated with 25% MC 
medium or 25% RPMI medium for 24 hours to assess the effects on macrophage-derived 
factors on adipocyte production of MCP-1, IL-6 and IL-1β. A separate group of 
adipocytes were also incubated with or without 5 ng/ ml of TNF-α for 24 hours to 
determine if the augmentation of inflammatory molecule production is induced by TNF-α 
production. The results show that gene expression of MCP-1, IL-6 and IL-1β in 
adipocytes is increased by factors produced by macrophages. The increase is also 
observed in adipocytes incubated with 5 ng/ ml TNF-α, suggesting that TNF-α is a key 
participant in the proinflammatory response of adipocytes. 
3.2.1.1 MC medium increases MCP-1 gene expression in adipocytes with 25% MC 
medium stimulation 
MCP-1 gene expression was increased 22-fold when incubated with 25% MC medium 
when compared to MCP-1 gene expression in control adipocytes (Figure 3.1A). 
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3.2.1.2 TNF-α stimulates MCP-1 gene expression in adipocytes 
MCP-1 gene expression were increased 55-fold when incubated with 5 ng/ ml TNF-α (P 
< 0.001; Figure 3.1A). 
3.2.1.3 MC medium increases IL-6 gene expression in adipocytes 
It is observed that IL-6 gene expression in adipocytes incubated with 25% MC medium 
was increased 467-fold compared to controls (P < 0.001; Figure 3.1B). 
3.2.1.4 TNF-α stimulates IL-6 gene expression in adipocytes  
IL-6 gene expression in cells treated with 5 ng/ ml TNF-α increased 51-fold (P < 0.001; 
Figure 3.1B) compared to controls. 
3.2.1.5 MC medium increases IL-1β gene expression in adipocytes 
IL-1β gene expression was increased 4.2-fold in cells treated with 25% MC medium 
compared to controls (P < 0.001; Figure 3.1C). 
3.2.1.6 TNF-α stimulates IL-1β gene expression in adipocytes  
IL-1β gene expression increased 8.6-fold in cells treated with 5 ng/ ml TNF-α medium 
compared to control cells (P < 0.001; Figure 3.1C).  
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Figure 3.1 Gene expression of MCP-1, IL-6 and IL-1β in adipocytes stimulated with 
25% MC medium or TNF-α 
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Gene expression of MCP-1 (A), IL-6 (B) and IL-1β (C) in human primary adipocytes (day 13 
post differentiation) stimulated with 25% MC medium or 5ng/ ml TNF-α. Cell culture 
maintenance medium was replaced with 25% MC medium in maintenance medium (25% 
MC) on day 13 post-differentiation. For the TNF-α study, medium was replaced with TNF-α 
in 25% RPMI (25% RPMI + 5ng/ ml TNFα). Medium for a group of cells was replaced with 
25% RPMI-1640 in maintenance medium (25% RPMI) as a control. Cells were harvested 
after 24 hours. Gene expression in adipocytes incubated with 25% MC medium, measured by 
real-time PCR and normalised to β-actin, are expressed relative to control. Results are given 
as means ± SD for groups of 6. ***P < 0.001 vs control (unpaired Student’s t-test). 
(A) 
(B) 
(C) 
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3.2.2 Protein secretion of MCP-1 and IL-6 by adipocytes stimulated with 
macrophage-conditioned medium or TNF-α 
Protein release of MCP-1, IL-6 and IL-1β by adipocytes was measured as concentrations 
in cell culture medium by ELISA. IL-1β levels could not be established from ELISA 
analysis as the levels produced by adipocytes in 1 ml of medium were lower than the 
detection limit of the method. 
3.2.2.1 MCP-1 production was increased by MC medium 
MCP-1 release by adipocytes treated with 25% MC medium was increased 40-fold 
compared to the basal MCP-1 production by control adipocytes (P < 0.001; Figure 3.2A) 
after correcting for macrophage-secreted MCP-1 in 25% MC medium (52.9 ± 0.8 pg/ ml) 
3.2.2.2 IL-6 production was increased by MC medium 
IL-6 release by adipocytes treated with 25% MC medium was increased 1124-fold (P < 
0.001; Figure 3.2) after correcting for basal levels of IL-6 in 25% MC medium (12.26 ± 
0.06 pg/ ml). 
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Figure 3.2 MCP-1 and IL-6 release by adipocytes stimulated with 25% MC medium 
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MCP-1 and IL-6 protein levels in cell culture medium of adipocytes were measured by 
ELISA. Basal levels of MCP-1 and IL-6 in 25% MC medium were determined by ELISA 
with a mean of 52.9±0.8 pg/ ml and 12.26±0.06 pg/ ml respectively. Results are given as 
means ± SD for groups of 3-4 for IL-6, groups of 6 for MCP-1. ***P < 0.001 vs control 
(25% RPMI; Unpaired student’s t-test). 
(A) 
(B) 
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3.3 Effects of macrophage-secreted factors on adipokine 
production by human primary adipocytes  
3.3.1 Gene expression of adiponectin and ZAG 
3.3.1.1 MC medium decreases adiponectin gene expression 
Groups of cells treated as described in section 3.2.1 were also measured for adipokine 
mRNA level. There was an 8-fold decrease in the gene expression level of adiponectin in 
adipocytes stimulated by 25% MC medium, compared to its basal levels in unstimulated 
adipocytes (P < 0.001; Figure 3.3A). 
3.3.1.2 TNF-α decreases adiponectin gene expression 
Cells treated with 5 ng/ ml of TNF-α showed a 2.7-fold decrease in adiponectin gene 
expression compared to basal expression levels in unstimulated adipocytes (P < 0.001; 
Figure 3.3A). 
3.3.1.3 MC medium decreases ZAG gene expression 
There was a 2.2-fold decrease in ZAG gene expression of adipocytes incubated with 25% 
MC medium (P < 0.001; Figure 3.3B) compared to basal expression levels in 
unstimulated adipocytes. The result for 25% MC treated cells is also in agreement with a 
previous ZAG study conducted in the department (Gao, 2010) where ZAG gene 
expression decreased similarly in adipocytes treated with neat (100%) MC medium. 
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3.3.1.4 TNF-α decreases ZAG gene expression 
ZAG gene expression significantly decreased 2-fold in adipocytes stimulated with 5ng/ 
ml TNF-α when compared to basal levels in unstimulated adipocytes (P = 0.033; Figure 
3.3B). 
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Figure 3.3 Relative expression of adiponectin and ZAG mRNA in adipocytes 
stimulated with 25% MC or TNF-α 
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Cell culture maintenance medium was replaced with 25% macrophage-conditioned 
medium in maintenance medium (25% MC) on day 13 post-differentiation. Cells were 
harvested after 24 hours. A separate group of cells were treated with 5ng/ ml TNF-α in 
25% RPMI. Cells incubated in 25% RPMI or maintenance medium (MM) were used as a 
control. mRNA expression in adipocytes treated with 25% MC medium treated cells or 
TNF-α, measured by real-time PCR and normalised to β-actin, are expressed relative to 
controls. Results are given as means ± SD for groups of 6. **P < 0.01, ***P < 0.001 vs 
control (Unpaired student’s t-test). 
 
(A) 
(B) 
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3.3.3 Adiponectin and ZAG production by adipocytes stimulated with 25% MC 
medium or TNF-α 
3.3.3.1 25% MC medium stimulation suppresses adiponectin release 
Treatment with 25% MC medium for 48 hours induced a statistically significant 3.4-fold 
reduction of adiponectin production by human primary adipocytes in comparison to basal 
adiponectin release by unstimulated adipocytes (P < 0.001; Figure 3.4A). 
3.3.3.2 25% MC medium stimulation suppresses ZAG release 
25% MC medium induced a 2.2-fold decrease in ZAG production by human primary 
adipocytes over a 48 hour period (P < 0.001; Figure 3.4B). 
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Figure 3.4 Adiponectin and ZAG production by human primary adipocytes 
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Cell culture maintenance medium was replaced with 25% RPMI-1640 in maintenance 
medium (25% RPMI) as a control or 25% macrophage-conditioned medium in 
maintenance medium (25% MC) on day 13 post-differentiation. Medium was collected 
after 48 hours. Adiponectin (A) and ZAG (B) concentrations in the culture medium of 
adipocytes were measured by real-time PCR. Results are given as means ± SD for groups 
of 3-4 for adiponectin, groups of 6 for ZAG. ***P < 0.001 vs control (Unpaired student’s 
t-test). 
(A) 
(B) 
105 
 
3.4 Activation of NF-κB and MAPK signalling pathways in 
adipocytes by macrophage-conditioned medium 
IκBα is a member of a family of intracellular proteins that inhibits NF-κB – a protein 
complex associated with proinflammatory gene transcription. IκBα masks nuclear 
localization signals of NF-κB proteins and keeps them sequestered in an inactive state in 
the cytoplasm. A decrease in anti-inflammatory gene expression is also known to be due 
to NF-κB’s inhibitory effect on PPAR-γ-mediated transcriptional activity (Suzawa, 
2003). Phosphorylation of serine residues in NF-κB p65 is required to elicit a 
conformational change to allow efficient recruitment of transcriptional cofactors (e.g. 
CBP) for activation of NF-κB pathways (Zhong et al., 1998). p38 MAPK is the subunit in 
the mitogen-activated kinase (MAPK) pathway and its activation is required for 
transcription of TNF-α, IL-1β and the transactivation of NF-κB p65 subunits in TNF-α 
mediated IL-6 gene expression (Guan et al.,1998; Vanden Berghe et al., 1998). 
3.4.1 Protein abundance of IκBα is decreased and phosphorylated NF-κB p65 
increased in adipocytes treated with 25% MC medium 
Prior to this section, it has been observed that 25% MC medium increased the expression 
of proinflammatory molecules (MCP-1, IL-6 and IL-1β) and decreased the expression of 
anti-inflammatory molecules adiponectin and ZAG. In line with results from the gene 
expression profile, MC medium had a stimulatory effect on the NF-κB signalling 
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pathway. The protein abundance of IκBα was decreased and phosphorylated NF-κB p65 
increased, consistent with the activation of NF-κB. 
3.4.1.1 MC medium decreases IκBα protein abundance 
MC medium stimulated adipocytes had a 3.4-fold decrease in IκBα levels compared to 
basal levels in control adipocytes (Figure 3.5; P = 0.0032). 
3.4.1.2 MC medium increases phosphorylated NF-κB p65 protein abundance 
A significant increase (1.7-fold) in phosphorylated NF-κB p65 protein abundance in 
stimulated adipocytes was also observed (Figure 3.6; P = 0.0301), in comparison to basal 
levels in control adipocytes. 
3.4.2 MC medium increases protein abundance of phosphorylated p38 MAPK in 
adipocytes 
3.4.2.1 Phosphorylated p38 MAPK levels increase with 25% MC medium stimulation 
Phosphorylated p38 MAPK levels were increased 2.8-fold with 25% MC medium 
stimulation (Figure 3.7; P = 0.0202) when compared to basal levels in control adipocytes.
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IκBα protein expression in human primary adipocytes incubated with 25% RPMI or 25% 
MC medium for 24 hours. (A) Protein expression in cell lysates were analysed by 
Western blotting and GAPDH was used as loading control. (B) Densitometric analysis of 
signal intensity was used for semi-quantitative analysis of IκBα levels. Data are means ± 
SD for groups of 3, normalised to GAPDH levels. **P < 0.01 vs controls (Unpaired 
student’s t-test) 
  
IκBα 
GAPDH 
(A) 
(B) 
25% RPMI    25% MC 
Figure 3.5 IκBα protein expression in human primary adipocytes stimulated with 25% 
MC medium 
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Phosphorylated NF-κB p65 protein expression in human primary adipocytes incubated 
with 25% RPMI or 25% MC medium for 24 hours. (A) Protein expression in cell lysates 
was analysed by Western blotting and GAPDH was used as loading controls. (B) 
Densitometric analysis of signal intensity was used for semi-quantitative analysis of 
phosphorylated NF-κB p65 levels. Data are means ± SD for groups of 3, normalised to 
GAPDH levels. *P < 0.05 vs controls (Unpaired student’s t-test). 
  
(A) 
(B) 
Phos-p65 
GAPDH 
25% RPMI          25% MC 
Figure 3.6 Phosphorylated NF-κB p65 protein expression in human primary 
adipocytes stimulated with 25% MC medium 
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Phosphorylated p38 MAPK protein expression in human primary adipocytes incubated 
with 25% RPMI or 25% MC medium for 24 hours. (A) Protein expression in cell lysates 
was analysed by western blotting and GAPDH was used as loading controls. (B) 
Densitometric analysis of signal intensity was used for semi-quantitative analysis of 
phosphorylated p38 MAPK levels. Data are means ± SD for groups of 3, presented 
relative to controls and normalised to GAPDH levels. *P < 0.05 compared to controls 
(Unpaired student’s t-test). 
(A) 
(B) 
Phos-p38 
GAPDH 
25% RPMI       25% MC 
Figure 3.7 Phosphorylated p38 MAPK protein expression in human primary 
adipocytes stimulated with 25% MC medium 
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Chapter 4  
The effects of calcitriol supplementation on 
inflammatory response in human primary adipocytes 
111 
 
4.1 Introduction 
Calcitriol, a specific ligand of VDR, was used to treat adipocytes before subjecting them 
to inflammatory stress to assess the efficacy of calcitriol supplementation on 
inflammation caused by macrophage-produced factors in the SVF. To understand the 
specific effect that macrophage-produced cytokines might have on adipocytes, cells were 
incubated with human recombinant TNF-α and concurrently treated with calcitriol to 
study if the cytokinic profile parallels that of the cells subjected to macrophage-produced 
inflammatory stimuli. A transmigration assay was also performed to study the chemotaxis 
of macrophages to a simulated adipose tissue environment in inflammation. The same 
study was applied to cells treated with calcitriol to determine if calcitriol supplementation 
to adipocytes could potentially reduce the effects of chemotactic factors responsible for 
the enhancement of the inflammatory response. 
4.2 The effects of calcitriol on the production of 
proinflammatory mediators by adipocytes 
4.2.1 Calcitriol has no effect on basal expression of genes related to inflammation 
4.2.1.1 Calcitriol does not affect gene expression of proinflammatory mediators in 
adipocytes 
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One-way ANOVA analysis with post-hoc Bonferroni’s t-tests showed that there were no 
significant differences in gene expression of MCP-1, IL-6 and IL-1β between calcitriol 
supplemented and unsupplemented cells (Figure 4.1).  
4.2.2 Calcitriol decreases basal production of MCP-1 and IL-6 by adipocytes 
4.2.2.1 Calcitriol reduces MCP-1 release by adipocytes 
Protein release data (Figure 4.2), in contrast to mRNA data, showed a highly significant 
1.3-fold decrease in MCP-1 for low dose calcitriol supplementation and a 3.1-fold 
decrease in MCP-1 for high dose supplementation (P = 0.0054 for low dose, P < 0.001 
for high dose). 
4.2.2.2 Calcitriol reduces IL-6 release by adipocytes 
IL-6 release by adipocytes also decreased 1.6-fold for both high and low dose 
supplemented groups (P = 0.0021 for low dose, P < 0.001 for high dose). 
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Figure 4.1 Gene expression of proinflammatory mediators in adipocytes pretreated 
with calcitriol  
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MCP-1 (A), IL-6 (B), IL-1β (C) gene expression in cells supplemented with calcitriol. 
Cells were treated on day 11 post-differentiation with varying concentrations of calcitriol 
(VD3) in 25% RPMI-1640 medium in maintenance medium (25% RPMI). The incubation 
medium was replaced on day 13 with fresh 25% RPMI with the same corresponding 
calcitriol concentrations and harvested after 24 hours. (NT, No treatment; 10-11M; 10-8M) 
mRNA expression was measured by real-time PCR and normalised to β-actin. Results are 
given as means ± SD for groups of 6. 
(A) (B) 
(C) 
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Figure 4.2 MCP-1 and IL-6 production by adipocytes pretreated with calcitriol 
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MCP-1 (A) and IL-6 (B) release from adipocytes supplemented with calcitriol. Cells 
were treated on day 11 post-differentiation with varying concentrations of calcitriol 
(VD3) in maintenance medium containing 25% RPMI-1640 medium. The incubation 
medium was replaced on day 13 with fresh 25% RPMI with the same corresponding 
calcitriol concentrations. Cell medium was collected after 24 hours; MCP-1 and IL-6 
concentrations were determined by ELISA. Results are given as means ± SD for groups 
of 4-6. **P < 0.01, ***P < 0.001 vs untreated controls (One-way ANOVA) 
(A) 
(B) 
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4.2.3 Effect of calcitriol on gene expression of proinflammatory mediators in 
adipocytes with proinflammatory stimulation 
To study the effects of calcitriol on MC medium-induced inflammatory response in 
adipocytes, cells were treated with fresh maintenance medium with low dose (10-11M) 
and high dose (10-8M) calcitriol on day 11 post-differentiation for 48 hours. A group of 
cells incubated in only fresh maintenance medium was maintained simultaneously as a 
control. On day 13 post-differentiation, the cell culture medium was replaced with 25% 
MC medium with low and high concentrations of calcitriol (10-11M, 10-8M). A group of 
cells incubated in 25% MC medium without calcitriol treatment and another group of 
cells maintained in 25% RPMI medium without calcitriol treatment was maintained as a 
control. 
To study the effect of calcitriol supplementation on TNF-α mediated inflammatory 
response in adipocytes, day 11 adipocytes were pretreated with calcitriol (10-11M or 10-
8M) for 48 hours. On day 13 post-differentiation the cell culture medium was replaced 
with 25% RPMI with 5 ng/ ml of TNF-α with calcitriol at low and high dose 
concentrations (10-11M, 10-8M). Similarly, a group of cells incubated in 25% RPMI with 
5 ng/ ml of TNF-α and another group of cells maintained in only 25% RPMI medium was 
used as controls. For multiple-group comparisons, the data was statistically tested with 
One-way ANOVA with post-hoc Bonferroni comparisons. 
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4.2.3.1 Calcitriol supplementation decreases MCP-1 and IL-1β gene expression 
There were no observed changes in MCP-1, IL-6 and IL-1β gene expression of low-dose 
calcitriol supplemented adipocytes stimulated with 25% MC medium (Figure 4.3). The 
inclusion of a 25% RPMI control served to ensure that MC medium stimulation did 
occur. High dose calcitriol treatment (10-8M) significantly decreased MCP-1 (P = 0.0031) 
and IL-1β (P = 0.0063) gene expression. However, the reduction in IL-6 gene expression 
was not considered to be statistically significant. 
4.2.3.2 Gene expression of MCP-1, IL-6 and IL-1β in adipocytes stimulated with TNF-α 
There was no statistical significance in changes observed in MCP-1 gene expression of 
adipocytes with both high (10-8M) and low dose (10-11M) calcitriol supplemented 
samples compared to unsupplemented cells upon TNF-α stimulation (Figure 4.3A). 
Similarly, calcitriol supplementation had no statisitically significant effect on IL-6 gene 
expression (Figure 4.3B) and IL-1β gene expression (Figure 4.3C). 
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Figure 4.3 Gene expression of MCP-1, IL-6 and IL-1β in calcitriol-supplemented 
adipocytes stimulated with 25% MC medium 
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MCP-1, IL-6 and IL-1β gene expression in calcitriol-supplemented adipocytes (10-11M or 
10-8M) treated with 25% MC medium and 5 ng/ ml TNF-α. The cell medium was 
replaced on day 13 with fresh 25% MC medium with the same corresponding calcitriol 
concentrations and harvested after 24 hours. Results are given as means ± SD for groups 
of 6 for 25% MC medium study, 3-4 for TNF-α study. *P < 0.05, **P < 0.01 vs untreated 
stimulated controls. †††P < 0.001 vs unstimulated controls (One-way ANOVA). 
(A) 
(B) 
(C) 
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4.2.3.3 Production of MCP-1 and IL-6 by calcitriol-supplemented adipocytes stimulated 
with MC medium. 
The MCP-1 and IL-6 produced by adipocytes was measured by ELISA. MCP-1 levels 
were decreased significantly after 24 hours of incubation with high dose calcitriol 
treatment (P = 0.007; Figure 4.4A). MCP-1 levels did not decrease significantly with low 
dose calcitriol. There were also significant reductions in IL-6 release by adipocytes 
incubated with both low dose (P = 0.001; Figure 4.4B) and high dose calcitriol (P = 
0.009). 
4.2.3.4 MCP-1 and IL-6 production by calcitriol-supplemented adipocytes stimulated 
with TNF-α 
There was no significant change in MCP-1 concentration in the medium of calcitriol-
supplemented adipocytes (Figure 4.4A). IL-6 concentration was significantly decreased 
in adipocytes with high dose calcitriol supplementation (P = 0.023; Figure 4.4B) 
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Figure 4.4 MCP-1 and IL-6 concentration in medium of calcitriol-supplemented 
adipocytes stimulated with 25% MC medium and TNF-α 
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MCP-1 and IL-6 measured as the concentrations in cell culture medium of adipocytes 
treated as described in Figure 4.3. Results are given as means ± SD for groups of 6 for 
MCP-1, 3-4 for IL-6 for the MC study; groups of 6 for the TNF-α study. *P < 0.05, **P < 
0.01 vs MC-stimulated controls. †††P < 0.001 vs unstimulated controls (One-way 
ANOVA). 
(A) 
(B) 
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4.3 The effects of calcitriol on the production of the 
adipokines, adiponectin and ZAG, by human adipocytes 
4.3.1 Calcitriol increases basal adiponectin and ZAG transcription in adipocytes 
with MC medium stimulation 
Figure 4.5 shows the effects of low and high dose calcitriol supplementation on basal 
gene expression levels of adiponectin and ZAG in adipocytes. 
4.3.1.1 High dose calcitriol increases basal adiponectin gene expression 
There was a 2-fold increase in adiponectin gene expression (P = 0.001) in adipocytes 
with high-dose (10-8M) calcitriol supplementation in comparision to controls (Figure 
4.5A). Adiponectin levels did not change significantly with low dose (10-11M) calcitriol 
treatment (Figure 4.5A). 
4.3.1.2 Low and high dose calcitriol increases basal ZAG gene expression levels 
ZAG gene expression in adipocytes increased with both low dose (P = 0.039) and high 
dose (P < 0.001) calcitriol supplementation in comparison to controls (Figure 4.5B). 
4.3.2 Effects of calcitriol on basal adiponectin and ZAG production by adipocytes 
Calcitriol supplementation did not cause any significant effect on basal adiponectin 
release by adipocytes (Figure 4.6A). A significant decrease in ZAG release (P = 0.009) 
was observed with low dose calcitriol supplementation of adipocytes but there was no 
effect on ZAG release of high dose supplemented adipocytes (Figure 4.6B). 
121 
 
4.3.3 Effects of calcitriol on gene expression of adiponectin and ZAG in adipocytes 
stimulated with MC medium 
Figure 4.7 shows the effects of low and high dose calcitriol supplementation on 
adiponectin and ZAG gene expression in adipocytes stimulated with 25% MC medium. 
4.3.3.1 Effects of calcitriol supplementation on adiponectin gene expression of 
adipocytes stimulated with MC medium 
Adiponectin gene expression was decreased in low dose calcitriol supplemented 
adipocytes stimulated with 25% MC medium in comparison to controls without calcitriol 
supplementation (Figure 4.7A; P = 0.018). However, high dose calcitriol supplementation 
partially reversed the inhibitory effect that 25% MC medium had on adiponectin gene 
expression (P = 0.017). 
4.3.3.2 High dose calcitriol reverses the inhibitory effect of MC medium on ZAG gene 
expression 
ZAG gene expression significantly increased (Figure 4.7B; P = 0.004) with high dose 
supplementation whereas the increase in ZAG gene expression was not statistically 
significant in low dose supplemented cells. 
4.3.4 Effects of calcitriol on adiponectin and ZAG release by adipocytes stimulated 
with MC medium 
Low-dose calcitriol treatment had no effect on MC medium-induced decrease in 
adiponectin release by adipocytes. There was a reduction in adiponectin levels with high 
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dose calcitriol supplemented adipocytes stimulated with MC medium (P < 0.001). 
Calcitriol supplementation did not reverse the inhibitory effect of MC medium on ZAG 
production over the same time period (Figure 4.8). 
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Figure 4.5 Gene expression of adiponectin and ZAG in adipocytes treated with 
calcitriol 
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Adiponectin and ZAG gene expression in calcitriol supplemented human adipocytes. 
Cells were harvested after 24 hours of incubation. mRNA expression was determined by 
real-time PCR and normalised to β-actin. Results are given as means ± SD for groups of 
6. †P < 0.05, ††P < 0.01 and †††P < 0.001 compared with unsupplemented controls. (One-
way ANOVA). 
 
  
(A) 
(B) 
124 
 
Figure 4.6 Adiponectin and ZAG production by adipocytes treated with calcitriol 
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Adiponectin and ZAG concentration in cell culture medium of adipocytes incubated with 
calcitriol for 48 hours, measured by ELISA. Results are given as means ± SD for groups 
of 4 for adiponectin and for ZAG. ††P < 0.01 compared with unsupplemented controls 
(One-way ANOVA). 
 
(A) 
(B) 
125 
 
Figure 4.7 Gene expression of adiponectin and ZAG in calcitriol supplemented 
adipocytes stimulated with 25% MC medium 
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Adiponectin and ZAG gene expression in calcitriol-supplemented human adipocytes. 
Cells were harvested after 24 hours of incubation with MC medium for ZAG and leptin 
and 48 hours incubation with MC medium for adiponectin. mRNA expression was 
determined by real-time PCR and normalised to β-actin. Results are given as means ± SD 
for groups of 6. *P < 0.05, **P < 0.01 vs unsupplemented, MC-stimulated controls. †††P 
< 0.001 vs unstimulated controls (One-way ANOVA). 
 
(A) 
(B) 
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Figure 4.8 Adiponectin and ZAG release from calcitriol-supplemented adipocytes 
stimulated with 25% MC medium 
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Adiponectin and ZAG concentration in cell culture medium of calcitriol-supplemented 
adipocytes stimulated with 25% MC medium for 48 hours, measured by ELISA. Results 
are given as means ± SD for groups of 4 for adiponectin and groups of 6 for ZAG. ***P 
< 0.001 compared with unsupplemented, stimulated controls. †††P < 0.001 compared with 
unstimulated controls (One-way ANOVA). 
 
(A) 
(B) 
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4.4 The effects of calcitriol on the intracellular signalling 
involved in inflammatory response in human adipocytes 
4.4.1 Calcitriol supplementation reverses the effects of MC medium on IκBα, 
phosphorylated NF-κB p65 and phosphorylated p38 MAPK in adipocytes 
As observed before in Chapter 3, IκBα protein expression in adipocytes was decreased 
when adipocytes were exposed to inflammatory molecules while phosphorylated NF-κB 
p65 and phosphorylated p38 MAPK expression were increased, suggesting that the 
activation of NF-κB and MAPK signalling pathways are central to the resulting 
inflammatory response observed in adipocytes. Both high and low dose calcitriol 
supplementation was observed to restore the intracellular signalling profile altered by 
proinflammatory stimuli from 25% MC medium or TNF-α.  
4.4.1.1 Calcitriol supplementation attenuates the decrease of IκBα induced by MC 
medium 
No increase in basal IκBα production was observed with low dose. However, at high dose 
supplementation, IκBα production was increased (P = 0.042) in unstimulated adipocytes. 
In the 25% MC medium stimulated cells, high doses of calcitriol were able to 
significantly reverse (P = 0.005; Figure 4.9) the decrease in IκBα protein levels. There 
was no significant change in IκBα levels in adipocytes supplemented with low doses of 
calcitriol. 
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4.4.1.2 Calcitriol supplementation attenuates the increase in phosphorylated NF-κB 
p65 protein abundance induced by MC medium 
Phosphorylated NF-κB p65 protein expression was decreased with low dose and high 
dose calcitriol supplementation (Figure 4.10) in unstimulated adipocytes although the 
decreases were not statistically significant. Elevated levels of phosphorylated NF-κB p65 
in adipocytes stimulated with 25% MC medium were also observed to return to similar 
levels in both the low dose (P = 0.003) and high dose (P = 0.033) supplementation 
groups. 
4.4.1.3 Calcitriol supplementation attenuates the increase in phosphorylated p38 
MAPK protein abundance induced by MC medium 
Basal levels of phosphorylated p38 MAPK decreased with high dose calcitriol 
supplementation (P = 0.025; Figure 4.11). In adipocytes stimulated with 25% MC 
medium, levels of phosphorylated p38 MAPK also decreased significantly with low dose 
calcitriol supplementation (P = 0.007) and high dose calcitriol supplementation (P = 
0.014) when compared to unsupplemented cells stimulated with 25% MC medium 
(Figure 4.11). 
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Figure 4.9 IκBα protein expression in human adipocytes supplemented with 
calcitriol 
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Figure 4.10 Phosphorylated NF-κB p65 protein expression in human adipocytes 
supplemented with calcitriol 
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Figure 4.11 Phosphorylated p38 MAPK protein expression in human adipocytes 
supplemented with calcitriol 
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4.6 The effects of calcitriol on monocyte migration 
4.6.1 Calcitriol supplementation decreases THP-1 monocyte migration 
The medium of calcitriol supplemented adipocytes (consisting of 25% RPMI) induced a 
highly significant decrease in THP-1 monocyte migration (Figure 4.12E) compared to 
controls and this effect was observed for both low dose (10-11M; P < 0.001) and high dose 
(10-8M; P < 0.001) calcitriol supplemented groups. Estimated cell numbers of control 
groups were compared to serum-supplemented and unsupplemented DMEM medium to 
correct the effect on cell migration mediated by foetal bovine serum and DMEM 
medium. 
4.6.2 Effects of calcitriol supplementation on THP-1 cell migration by adipocytes 
stimulated with MC medium 
The medium collected from adipocytes incubated with 25% RPMI or 25% MC medium 
was used for the THP-1 migration assay. As shown in Figure 4.13, THP-1 monocyte 
migration was significantly increased in the medium of MC incubated adipocytes 
compared to adipocytes incubated with 25% RPMI. Low dose (10-11M) calcitriol 
supplementation of adipocytes incubated with 25% MC medium did not alter THP-1 cell 
migration (Figure 4.13E). There was a significant increase of THP-1 cell migration in the 
high dose group (10-8M: P = 0.002). 
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4.6.3 Calcitriol supplementation does not decrease THP-1 monocyte migration by 
adipocytes stimulated with TNF-α 
The medium collected from adipocytes incubated with and without 5ng/ml TNF-α in 
25% RPMI medium was used for the THP-1 migration assay. According to Figure 4.14E, 
TNF-α significantly increased the THP-1 monocyte migration compared to controls. 
There was no significant effect of calcitriol supplementation on THP-1 cell migration in 
TNF-α stimulated adipocytes. 
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4.7 The effects of calcitriol on gene expression of VDR in 
human adipocytes 
4.7.1 Calcitriol enhances VDR gene transcription 
4.7.1.1 Calcitriol increases basal VDR expression 
Figure 4.15 shows the level of VDR mRNA expression in MC medium and TNF-α 
stimulated adipocytes. Low dose calcitriol supplementation did not cause a difference in 
VDR gene expression levels. High dose calcitriol supplementation, however, induced a 
2.3-fold increase in basal VDR expression (P = 0.043).  
4.7.1.2 Calcitriol further enhances VDR gene expression in adipocytes stimulated by 
25% MC medium 
Figure 4.15 shows increased VDR gene expression in calcitriol-supplemented adipocytes 
stimulated with MC medium compared to unsupplemented, MC medium-stimulated 
adipocytes. There was a 2.9-fold increase in VDR gene expression with high dose 
calcitriol supplementation in 25% MC medium stimulated adipocytes (P = 0.012) 
compared to unsupplemented controls. Low dose calcitriol supplementation also 
increased VDR gene expression but this was not statistically significant. 
4.7.1.3 Calcitriol increases VDR gene expression in TNF-α stimulated adipocytes 
As shown in Figure 4.15, VDR gene expression was increased by TNF-α. Low dose 
calcitriol supplementation in adipocytes stimulated with TNF-α did not affect VDR gene 
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expression. In high dose supplementation however, a 3.2-fold increase in VDR gene 
expression was observed compared to unsupplemented TNF-α-stimulated controls (P = 
0.034). 
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Figure 4.15 VDR gene expression in MC medium and TNF-α stimulated adipocytes 
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(A) Adipocytes incubated with calcitriol. (B) Adipocytes incubated with calcitriol 
stimulated with 25% MC medium. (C) Adipocytes incubated with calcitriol and 
stimulated with 5 ng/ml TNF-α. VDR gene expression was determined by real-time PCR 
and normalised to β-actin. Results are given as means ± SD for groups of 6. *P < 0.05 vs 
unsupplemented, MC medium-stimulated controls. †P < 0.05 vs unstimulated controls 
(One-way ANOVA). 
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4.8 Cytotoxicity assessment 
As shown in Figure 4.16, there were no significant differences in LDH release by 
adipocytes treated with MC medium in 48 hours. Therefore, neither macrophage-
conditioned media nor calcitriol with DMSO induced cell cytotoxicity. 
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Figure 4.16 LDH release from human adipocytes 
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Cytotoxicity was determined by the measurement of lactate dehydrogenase released into 
cell culture medium by human adipocytes. Cell medium collected from calcitriol-treated 
adipocytes were tested for LDH release. Cell culture medium of adipocytes were treated 
with calcitriol in 25% RPMI or 25% MC medium and collected after 48 hours. Results 
are given as means ± SD for groups of 4. 
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Chapter 5  
Discussion and conclusion  
143 
 
5.1 Introduction 
Adipose tissue is now considered to be a multifunctional endocrine organ secreting a 
wide range of protein factors collectively termed as adipokines (Trayhurn and Bing, 
2006). These adipokines have considerable effects on lipid and glucose metabolism, the 
alternative complement system, the renin-angiotensin system as well as energy balance. 
There is now a growing number of adipokines found to be involved in inflammation and 
these particular adipokines have been known to increase in circulating levels in obesity 
(Trayhurn and Wood, 2005). The raised levels of acute-phase proteins and inflammatory 
cytokines found in the systemic circulation has led to the postulation that obesity is 
characterised by a state of low-level chronic inflammation (Xu et al., 2003; Wellen and 
Hotamisligil, 2005). Medical dogma avers that excessive inflammation leads to lowered 
functionality of organs and the persistence of this inflammatory state promote the 
comorbid conditions associated with obesity, such as insulin resistance, Type 2 diabetes 
and cardiovascular disease. 
A considerable amount of research has been conducted over recent years to elucidate the 
mechanistic links between adipokinic inflammation and obesity comorbidities 
(Hotamisligil et al., 1996; Hirosumi et al., 2002; Perseghin et al. 2003; Cai et al. 2005). 
Macrophage-infiltration in adipose tissue provides an important mechanistic link between 
the obese state and an increase in cytokine production which may form the basis of 
chronic inflammation associated with obesity comorbidities (Weisberg et al., 2003). The 
vitamin D system is increasingly recognised to have a range of physiological functions 
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beyond calcium homeostasis and bone metabolism (Lin and White, 2004; Bikle, 2009). 
In particular, vitamin D3 is a strong candidate for the promotion of anti-inflammatory 
activity, given its immunomodulatory effects in several cell types (Deluca and Cantorna, 
2001; Wang et al., 2004; Chen et al., 2007). Vitamin D deficiency is also well-
documented in obesity and chronic inflammation (Hyppönen and Power, 2007; Timms et 
al. 2002). It is therefore one of the primary aims of this study to contribute to current 
knowledge of vitamin D3, particularly its possible role in alleviating inflammation in 
adipocytes. 
A simulated model of adipocyte inflammation was created by incubating adipocytes with 
macrophage-conditioned (MC) medium. This model was then used to study the efficacy 
of calcitriol supplementation in alleviating proinflammatory mediators expressed and 
released by human adipocytes. The potential involvement of NF-κB and MAPK 
signalling pathways was also studied. 
5.2 Macrophage-produced factors induce inflammatory 
responses in human adipocytes 
Chapter 3 demonstrates that macrophage-secreted factors increase inflammatory 
mediators produced by human primary adipocytes. The LDH assay showed that there 
were no significant differences in LDH production between cells treated with MC 
medium and cells treated with RPMI medium. Therefore it was concluded that the MC 
medium did not have a cytotoxic effect on adipocytes and any changes to gene expression 
or protein release were not due to cytotoxicity in adipocytes. The results show that gene 
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expression of MCP-1, IL-6 and IL-1β in human primary adipocytes was extensively 
upregulated when exposed to macrophage-produced factors. The increase in MCP-1 and 
IL-6 gene expression was substantiated with corresponding data of increased MCP-1 and 
IL-6 production measured in the culture medium of adipocytes. The data strongly suggest 
that adipocytes are a major source of MCP-1 and IL-6 production in the presence of 
macrophage infiltration, substantiating the findings by Sartipy and Loskutoff (2003). The 
study also shows that expression of these proinflammatory genes are stimulated by TNF-
α, a major cytokine produced by activated macrophages. 
The drastic increase in MCP-1 produced by adipocytes stimulated by MC medium is 
consistent with the increase in macrophage infiltration in adipose tissue in obesity. MCP-
1 fuels the paracrine loop between macrophages and adipocytes (Suganami et al., 2005). 
Elevated levels of MCP-1 increase the diapedesis of monocytes and macrophages and 
promote monocyte differentiation into macrophages and foam cells (Tabata et al., 2003). 
This effect was evident in the present study as the level of THP-1 monocyte migration 
was increased more than two-fold with macrophage-conditioned medium. Based on the 
present study and a previous study by Kanda et al. (2006), it is postulated that the THP-1 
chemotactic activity in the transmigration study was mainly attributed to the MCP-1 
content produced by stimulated adipocytes.  
A large increase in MCP-1 by adipocytes has important implications in modulating 
adipose tissue function. Sartipy and Loskutoff (2003) demonstrated that recombinant 
MCP-1 significantly inhibited insulin-mediated glucose uptake in cells by approximately 
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30%. Sartipy and Loskutoff also showed in the same study that exposure of adipocytes to 
MCP-1 can reduce adipsin, lipoprotein lipase, GLUT-4, PPAR-γ, aP2 and β3-adrenergic 
receptor expression. This suggests that excessive MCP-1 production that can result from 
adipocyte and macrophage crosstalk may play a major role in the pathogenesis of 
common obesity comorbidities such as insulin resistance and dyslipidaemia. 
The large increase in IL-6 produced by adipocytes stimulated with macrophage-secreted 
factors is an interesting key finding in this study. This study demonstrated a considerable 
increase in IL-6 levels produced by adipocytes stimulated with macrophage conditioned 
medium and TNF-α. The data also showed that IL-6 produced by adipocytes upon 
stimulation was considerably higher than that of IL-6 secreted by macrophages. This 
observation strongly suggests that most IL-6 found in adipose tissue in the occurrence of 
macrophage infiltration would be attributable to adipocytes, which is consistent with the 
observations in 3T3-L1 cells (Yamashita et al., 2007). The results also suggest that the 
proportion of IL-6 produced by macrophages compared to adipocytes in WAT after 
stimulation with inflammatory mediators may be much lower than 50%, as proposed by 
Fantuzzi (2005). TNF-α stimulation of human adipocytes in this study did not elicit an 
IL-6 production as high as that of macrophage-conditioned medium, indicating that other 
moieties produced by macrophages in the macrophage-conditioned medium may be 
involved in IL-6 regulation in adipocytes. Adipose tissue is a major source of IL-6 
production, accounting for 15-35% of circulating levels in the blood (Mohamed-Ali et 
al., 1997).  The results from the present study suggest that macrophage infiltration in 
adipose tissue could cause adipocytes to become a major source of IL-6 production.
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NF-κB is a key transcription factor that plays a pivotal role in TNF-α induced 
inflammatory gene expression in adipocytes (Cawthorn and Sethi, 2008). p38 MAPK 
also regulates the expression of many cytokines and chemokines in non-fat cells, 
transducing the effects of TNF-α in defined phosphorylation cascades (Kiriakis, 1999; 
Rydén et al., 2002). Although the role of p38 MAPK has been well studied in adipocyte 
differentiation and glucose metabolism, its role in the adipocyte inflammatory process is 
still unclear (Gehart et al., 2010). It is evident that the activation of these two pathways is 
central to activating the gene expression of inflammatory mediators, including genes 
encoding TNF-α and IL-6. The current data together with studies carried out by Zhu et al. 
(2008) suggest that MCP-1 production is mediated by NF-κB. In the current study, IκBα 
was decreased and phosphorylated NF-κB p65 was increased in adipocytes stimulated by 
MC medium, suggesting that there was an increase in NF-κB activation. In addition, 
phosphorylated p38 MAPK was increased by stimulation with MC medium and this is 
consistent with an increase in p38 MAPK activation. 
The relative expression of anti-inflammatory adipokines by adipocytes in the present 
study was also altered. Adiponectin and ZAG gene expression was downregulated by 
both macrophage-secreted factors and TNF-α. This is consistent with the recent findings 
by our group (Gao et al., 2010). Substantiating the gene expression data, the present 
study showed that MC medium induced a decrease in adipocyte release of adiponectin 
and ZAG by adipocytes. 
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Recent studies by our group showed a three-fold increase in ZAG gene expression in 
adipocytes treated with rosiglitazone, indicating the involvement of PPAR-γ action in 
regulating ZAG levels (Bao et al., 2005). PPAR-γ has been shown to regulate the 
transcription of many adipocyte-secreted proteins, including adiponectin and ZAG (Bao, 
2005; Gao, 2010). The downregulation of ZAG and adiponectin suggests that a common 
pathway, presumably PPAR-γ mediated, could be inhibited by NF-κB or MAPK 
activation. 
Taken together, the secretion of proinflammatory adipokines by adipocytes stimulated 
with macrophage-derived factors provides a likely explanation for raised levels of 
inflammatory mediators, which is associated with increased macrophage infiltration in 
adipose tissue in obesity. 
5.3 Calcitriol promotes anti-inflammatory activity in 
adipocytes 
This study has demonstrated that high dose calcitriol supplementation of adipocytes 
counteracted the increase in gene expression of MCP-1, IL-6 and IL-1β expression 
caused by macrophage medium stimulation. The data also showed a significant decrease 
in MCP-1 and IL-6 concentration in the medium of both MC medium stimulated 
adipocytes and unstimulated adipocytes, suggesting that calcitriol supplementation 
decreased the production of MCP-1 and IL-6. The analysis of LDH levels in cell culture 
medium showed that there were no significant differences between MC medium 
stimulated cells treated with calcitriol and control cells. Therefore any changes to the 
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gene expression or protein release were not due to cytotoxicity in adipocytes. Consistent 
with our results, a recent study has shown that calcitriol (10-7M) reduced MCP-1 mRNA 
and protein release by human adipocytes stimulated by TNF-α (Lorente-Cebrián et al., 
2011). 
Calcitriol supplementation also reduced the increase in MCP-1 and IL-6 gene expression 
caused by TNF-α stimulation in adipocytes. In addition, IL-6 release by adipocytes was 
lowered with calcitriol supplementation. The paralleled suppression of IL-6 production in 
both MC medium and TNF-α stimulated adipocytes with calcitriol treatment suggests that 
calcitriol reduces the proinflammatory effects induced by macrophage-derived factors in 
adipocytes. The results are consistent with the reduction in IL-6 production in 3T3-L1 
adipocytes supplemented with vitamin D3 and vitamin E (Lira et al., 2011). In vivo, 
vitamin D3 supplementation was shown to decrease serum IL-6 levels in clinical studies 
(Van den Berghe et al., 2003). However, the inhibition of MCP-1 release was not 
observed in calcitriol-treated adipocytes withz TNF-α stimulation, suggesting that 
calcitriol-mediated inhibition of MCP-1 release by MC medium may not be mediated 
primarily by the effect of TNF-α. 
The gene expression of anti-inflammatory adipokines in adipocytes was also significantly 
altered by calcitriol. Basal ZAG and adiponectin gene expression increased significantly 
in adipocytes with high dose calcitriol supplementation. High dose calcitriol 
supplementation in adipocytes also partially reversed the decrease in adiponectin and 
ZAG expression caused by MC medium stimulation. Adiponectin release was decreased 
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by calcitriol although there was no change in ZAG release levels. The results suggest that 
calcitriol also protects against the inhibitory effects of macrophage-derived factors by 
modulating the production of adiponectin and ZAG by human adipocytes. 
These results led to the postulation that calcitriol may act on transcription factors and 
activation pathways leading to proinflammatory gene expression. Thus the effect of 
calcitriol supplementation on the expression of proinflammatory intracellular signalling 
molecules was subsequently explored. Calcitriol supplementation was able to increase 
IκBα levels in a dose-dependent manner, while decreasing the levels of phosphorylated 
NF-κB p65 and p38 MAPK with both low and high dose supplementation. The increase 
in IκBα and decrease in phosphorylated NF-κB p65 induced by high dose calcitriol is 
consistent with a stronger anti-inflammatory secretion profile observed in adipocytes 
supplemented with high doses of calcitriol. NF-κB activation is known to promote MCP-
1 and IL-6 transcription in adipocytes (Zhu et al., 2008; Ruan et al., 2002). Similar 
effects of calcitriol on the inhibition of NF-κB have been reported in mouse embryonic 
fibroblasts (Chen et al., 2011). Interestingly, calcitriol has also been shown to decrease 
NF-κB activation in mesangial cells caused by macrophage accumulation in kidney 
glomeruli and interstitium (Zhang et al., 2007). Furthermore, it has been shown that the 
downregulation of MCP-1 production is also linked to the concurrent decrease of NF-κB 
and p38 MAPK (Fain and Madan, 2005). 
Taken together, it appears that vitamin D3 supplementation has an anti-inflammatory 
effect in adipocytes. The results of the study demonstrated that low dose calcitriol was 
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unable to effectively inhibit proinflammatory processes. A much more apparent anti-
inflammatory effect in adipocytes was observed with high dose calcitriol 
supplementation. This suggests the involvement of an intracellular competitive inhibitory 
effect that may be mediated by calcitriol. The data also suggests that vitamin D3 
supplementation has beneficial effects in limiting the proinflammatory changes induced 
by macrophage-secreted factors. It is not known if calcitriol stimulates anti-inflammatory 
cytokines produced by macrophages and further studies will be needed.  
Other interesting results include the detection of VDR gene expression in human 
adipocytes and the upregulation of VDR gene expression with high dose calcitriol 
supplementation. Interestingly, VDR gene expression was elevated in both MC medium 
and TNF-α stimulated adipocytes. These preliminary data suggest that VDR could be 
involved in the inflammatory response in adipocytes. Macrophages are known to produce 
both proinflammatory and anti-inflammatory cytokines (Opal and DePalo, 2000). Further 
studies, therefore, will be required to clarify the nature and regulation of VDR in 
adipocytes by macrophages. 
In conclusion, the study suggests that increasing the calcitriol concentration available to 
adipocytes has potential benefits for the reduction of the inflammatory response that may 
arise from the macrophage and adipocyte crosstalk that occurs in obesity. This supports 
the notion that increasing the intake or synthesis of vitamin D may lower the 
inflammatory response by adipose tissue. The study is limited to observations of cells 
treated with calcitriol prior to inflammatory challenge, which suggests that the anti-
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inflammatory effects seen may be a consequence of calcitriol availability at an early stage 
of adipocyte development. However, it is understood that adipocytes are renewed at an 
approximate rate of 10% annually for individuals of all ages and BMIs (Spalding et al., 
2008). This dynamic renewal of adipose tissue therefore presents opportunities for 
vitamin D pharmacotherapy of dysfunctional adipose tissue at the early stages of 
adipocyte development. However it is not known whether calcitriol will have anti-
inflammatory effects on obese adipose tissue which may have had interactions with 
macrophages for a longer period of time. More studies will be required to observe the 
effects of calcitriol on adipose tissue in longer term obesity, as they may respond 
differently to macrophages as well as pharmacotherapy. 
5.4 Limitations of the study and future work 
The concentration of IL-1β in adipocyte culture medium could not be measured by IL-1β 
ELISA development kits we acquired. It is possible that the release of IL-1β by 
adipocytes may be lower than the detection limit of the assay. There is a general 
consensus that most IL-1β found in adipose tissue is produced by the stromal vascular 
cells, which include resident macrophages. Given the comparatively high amount of IL-
1β produced by macrophages in 25% macrophage-conditioned medium used in the study, 
it was also not possible to effectively measure the differences in IL-1β production by 
adipocytes incubated in macrophage-conditioned medium. 
While the macrophages in the macrophage conditioned medium did induce an overall 
proinflammatory effect on adipocytes, it is not known whether this emulated the 
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behaviour of macrophages in obesity. It is understood that macrophages associated with 
the lean phenotype are activated by the alternative pathway and may promote an anti-
inflammatory effect. Adipose tissue macrophages recruited in obesity are also known to 
have unique properties compared to resident macrophages (Lumeng et al., 2007). Future 
studies should include the use of macrophages with a resultant cytokine secretion profile 
that is representative of macrophages in obesity. The effects of calcitriol may also be 
investigated in macrophages, as calcitriol has been shown in vitro to alternatively activate 
macrophages and downregulate proinflammatory cytokine production. 
TNF-α treated samples were not studied for adipokine expression and release due to the 
lack of time and resources for this dissertation. It is recommended that future work 
include studies on PPAR, C/EBPα and Akt detection to study the molecular mechanisms 
by which adiponectin and ZAG are regulated. Other possible signalling pathways that are 
VDR-related should be studied as well, such as the adenylate cyclase and PKC, of which 
upon activation increase and decrease VDR respectively. 
Because of its strong links to NF-κB and VDR signalling, as well as its role in glucose 
and lipid metabolism, PPARs have been identified as potential candidate genes to study 
for its role in inflammation and vitamin D action in adipocytes. The possible involvement 
of PPARs in inflammatory crosstalk between macrophages and adipocytes brings into 
question its role in insulin resistance and dyslipidaemia. The following section presents 
some pilot data on the effects of macrophage-secreted factors and vitamin D3 on the 
indicators of glucose and lipid metabolism. 
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Calcitriol improves glucose metabolism 
The pilot data showed a modulation of glucose metabolism in adipocytes incubated with 
macrophage-produced factors. Adipocytes stimulated with 25% MC medium has a 7.9-
fold decrease in GLUT-4 gene expression (P < 0.001; Figure 5.1) TNF-α also induced a 
3-fold decrease in GLUT-4 gene expression in adipocytes (P < 0.001), strongly 
suggesting the cytokine’s involvement in GLUT-4 regulation. Protein signalling studies 
also showed a decrease in GLUT-4 production (Figure 5.2). High dose calcitriol 
supplementation in a non-inflammatory environment increased GLUT-4 mRNA 
expression (P < 0.001). High dose calcitriol supplementation was also able to effect a 
similar increase in an inflammatory environment provided by macrophage medium (P < 
0.001). 
Expression of IRβ was slightly decreased with 25% MC medium incubation (Figure 5.3), 
which suggests a possible insulin/PI3K-dependent pathway that may be modulated by 
macrophage-secreted factors. Calcitriol supplementation did not appear to alter the levels 
of IRβ. It is postulated that proper insulin sensitivity experiments will need to be 
conducted to accurately determine the effect of macrophages on insulin sensitivity, which 
should include measurement of IRS-1 phosphorylation with insulin fasted specimens. 
 
  
155 
 
Figure 5.1 GLUT-4 mRNA expression in calcitriol-supplemented adipocytes 
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GLUT-4 mRNA expression of cells from calcitriol-treated groups incubated in 
conditioned outlined in sections 4.2.1 and 4.2.3. (A) GLUT-4 expression in calcitriol-
treated cells incubated in RPMI. (B) GLUT-4 expression in calcitriol-treated cells 
incubated in 25% MC medium. (C) GLUT-4 expression in calcitriol-treated cells 
incubated with 5ng/ml TNF-α. Results are given as means ± SD for groups of 6. (NT: 
non-treated.) ***P < 0.001 compared with untreated 25% MC controls. †††P < 0.001 
compared with untreated 25% RPMI medium incubated controls (One-way ANOVA). 
(A) (B) 
(C) 
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Figure 5.2 GLUT-4 protein production in calcitriol-supplemented adipocytes 
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GLUT-4 release from calcitriol-treated adipocytes incubated in 25% MC. Results are 
given as means ± SD for groups of 3. NT, non-treated. All comparisons were not 
significantly different compared with untreated 25% RPMI medium incubated controls (P 
> 0.05, One-way ANOVA).  
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Figure 5.3 IRβ expression in human primary adipocytes supplemented with 
calcitriol incubated with 25% MC medium 
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IRβ expression in calcitriol-supplemented human primary adipocytes as outlined in 
Figure 4.9. (A) Western blots of protein lysates of control and 25% MC medium 
incubated adipocytes. (B) Densitometric analysis of blots was used for semi-quantitative 
analysis of IRβ levels. (Calcitriol: VD3) Data are means ± SD for groups of 3, presented 
relative to controls and normalised to GAPDH levels. All comparisons assessed by One-
way ANOVA. 
(A) 
(B) 
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GAPDH 
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5.5 Conclusion 
Adipose tissue is now recognised as a major endocrine organ, as more adipokines are 
being uncovered and functions found for some of them. Consistent with previous studies, 
this study has shown that adipocytes play major roles in the inflammatory response by 
secreting large quantities of various proinflammatory adipokines in response to 
inflammatory stimuli by macrophage-conditioned medium and TNF-α. The results 
support the notion that adipose tissue has a key role in modulating inflammatory 
responses. 
This study demonstrated that supplementation of adipocytes with the active form of 
vitamin D3, calcitriol, decreased the production of several proinflammatory mediators in 
human primary adipocytes. A high dose (10-8M) of calcitriol supplementation was able to 
decrease the basal production of the proinflammatory mediators MCP-1 and IL-6 by 
human primary adipocytes. High dose calcitriol supplementation was also able to 
decrease the gene expression of MCP-1, IL-6 and IL-1β in adipocytes stimulated with 
macrophage-conditioned medium. In agreement with the gene expression data, MCP-1 
and IL-6 release was also decreased with calcitriol supplementation. High dose calcitriol 
led to a decrease in IL-6 release while had no effect on MCP-1 release from adipocytes 
stimulated with TNF-α, suggesting that the inhibitory effect of calcitriol may be elicited 
in concert with other factors produced by macrophages. 
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High dose calcitriol supplementation also led to a significant increase in basal gene 
expression of adiponectin and ZAG. Upon MC medium stimulation, high dose calcitriol 
supplementation partially reversed the inhibitory effects on adiponectin and ZAG gene 
expression. Calcitriol also partially restored the production of adiponectin by adipocytes 
although did not affect ZAG production. These data suggest that calcitriol promotes gene 
transcription of anti-inflammatory adipokines in human adipocytes. 
As the production of the proinflammatory mediators plays a role in macrophage 
infiltration into adipose tissue, the medium of calcitriol-supplemented adipocytes was 
used to assess THP-1 monocyte migration. This study showed that calcitriol decreased 
the chemoattractant ability of adipocytes as both low dose (10-11M) and high dose (10-
8M) calcitriol reduced THP-1 monocyte migration. 
High dose calcitriol significantly increased NF-κB IκBα protein expression and decreased 
levels of phosphorylated p38 MAPK in adipocytes. It also showed an inhibitory effect on 
protein abundance of p38 MAPK, a known activator of inflammatory cytokine 
expression. This suggests that calcitriol has a significant effect on modulating 
intracellular signalling that mediate the transcription of proinflammatory genes. 
Overall, macrophage-derived factors potently induced the inflammatory response in 
adipocytes; high dose calcitriol supplementation has a protective role by reducing the 
overproduction of proinflammatory mediators by human adipocytes. The study has also 
shown that the beneficial effect of calcitriol in adipocytes may be mediated via the 
inhibition of NF-κB and p38 MAPK signalling. 
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